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Abstract 
Hypothalamic neuropeptides orexin-A and orexin-B, and their receptors OX1 and OX2 were found 
in 1998 as regulators of appetite. Later, they have been shown to also regulate, for instance, arousal 
states, stress reactions, and the reward system. Orexin peptides and receptors have been researched, 
especially in the field of drug discovery; however many relevant biochemical properties remain 
partly unsolved, including the factors determining orexin ligand binding properties and ligand 
selectivity. The study of these factors was pursued in this thesis. 
Ligand selectivity was first studied here with chimaeric orexin receptors. With these 
chimaeras we mapped some of the molecular determinants of orexin receptors that are needed for 
the selectivity of orexin agonists and OX1-specific antagonist. The second quarter of the orexin 
receptor seems to be the most important area both for agonist and antagonist selectivity. However, 
for antagonist selectivity, the third quarter also seems to have a role. Orexin receptor binding 
properties were studied by determining the impact of extracellular calcium concentration on orexin 
ligand binding. Calcium has been known to have an important role in orexin signal transduction as 
stimulation of orexin receptors causes a strong elevation of intracellular calcium, and reduction of 
extracellular calcium attenuates that calcium increase. In addition, other orexin receptor signalling, 
mediated by certain phospholipases and kinases, for instance, is attenuated. It remains unknown, 
however, how calcium causes these effects. With [
125
I]-orexin-A, a clear decrease in binding was 
observed after reduction of the extracellular calcium concentration. Proper ligand binding is an 
important part of signal transduction, and indeed we saw a similar reduction also in the activities of 
phospholipase C (PLC) and adenylyl cyclase (AC). The concentration-relationship of calcium was 
identical for radioligand binding, PLC activation, and AC stimulation, while AC inhibition was 
more strongly attenuated. When the driving force for calcium influx was reduced with high-K
+
 
medium, the orexin-A-induced PLC activity was more strongly reduced than orexin-A binding. In 
addition, inhibition of the orexin receptor-operated calcium channels had a more pronounced effect 
on the PLC activity than on the binding. It is thus suggested that reduction of extracellular calcium 
concentration has a dual effect on orexin receptor signalling, both by inhibition of orexin binding 
and attenuation of the enzymatic activity. 
 Orexin-B has higher binding affinity for OX2 than OX1 receptor. Commercially available 
orexin-B variant, [Ala
11
, D-Leu
15
]-orexin-B, has been reported to display a higher selectivity for 
OX2 than the native orexin-B. However, we observed that [Ala
11
, D-Leu
15
]-orexin-B showed much 
lower OX2-selectivity than originally reported. In addition, the selectivity of both forms of orexin-B 
was dependent on the cell line. These findings may be caused by biased agonism of the orexin 
receptor, meaning that the orexin receptor can be found in multiple conformations, each of which 
can interact differently with an agonist. This result extends our knowledge of orexin ligand binding 
properties, and the phenomenon should be considered, for instance, when novel agonists for orexin 
receptors are screened.   
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Abbreviations 
[Ca
2+
]e  Extracellular calcium concentration 
[Ca
2+
]i  Intracellular calcium concentration 
2-AG  2-arachidonylglycerol 
aa  Amino acid 
AA  Arachidonic acid 
AC  Adenylyl cyclase 
Almorexant (2R)-2-[(1S)-6,7-dimethoxy-1-(2-[4-(trifluoromethyl)phenyl]ethyl)-3,4-
dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylethanamide 
AT1  Angiotensin II type 1 receptor 
BAT  Brown adipose tissue 
BRET  Bioluminescence resonance energy transfer 
BSA  Bovine serum albumin 
CB1  Cannabinoid receptor type 1 
Ch  Chimaera 
CHO  Chinese hamster ovary 
CNS  Central nervous system 
cPLA2  Cytosolic phospholipase A2 
DAG  Diacylglycerol 
DGL  Diacylglycerol lipase 
DMEM  Dulbecco’s Modified Eagle Medium 
DORA  Dual orexin receptor antagonist 
EMPA  N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-
ylmethyl-acetamide 
ER  Endoplasmic reticulum 
ERK  Extracellular signal-regulated kinase 
FCS  Fetal calf serum 
FDA  U.S Food and Drug Administration 
FRET  Fluorescence/Förster resonance energy transfer 
Gα  α subunit of the G-protein 
Gβγ  βγ subunit complex of the G-protein 
GABA  -aminobutyric acid 
GAP  GTPase-activating/-accelerating protein 
GEF  Guanine nucleotide exchange factor 
GF  Glass fiber 
GFP  Green fluorescent protein 
GIRK  G-protein-coupled inwardly rectifying potassium 
GPCR  G-protein-coupled receptor 
G-protein   Guanine nucleotide-binding protein 
GRK  G-protein-coupled receptor kinase 
GSK  GlaxoSmithKline 
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GTPase  Guanine triphosphatase 
HBM  Hepes-buffered medium 
HCS  High-content screening 
HEK  Human embryonic kidney 
HTS  High-throughput screening 
IP3  Inositol-1,4,5,-trisphosphate 
JAK  Janus kinase 
JNJ-10397049 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea 
KBM  K
+
-based medium 
MAFP  Methyl arachidonyl fluorophosphonate 
MAPK  Mitogen-activated protein kinase 
NaBM  Na
+
-based medium 
NPY  Neuropeptide Y 
OX1  OX1 orexin receptor 
OX2  OX2 orexin receptor 
PA  Phosphatidic acid 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PEI  Polyethyleneimine 
PIP2  Phosphatidylinositol-4,5-bisphosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PLA  Phospholipase A 
PLC  Phospholipase C 
PLD  Phospholipase D 
POMC  Proopiomelanocortin 
PVDF  Polyvinylide fluoride 
RAMP  Receptor activity-modifying protein 
REM  Rapid eye movement 
RGS  Regulator of G-protein signalling 
RT-PCR  Reverse transcription polymerase chain reaction 
ROC  Receptor-operated calcium channel 
SB-334867  1-(2-methyylbenzoxanzol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride 
SOC  Store-operated calcium channel 
SPA  Scintillation proximity assay 
STAT  Signal transducer and activator of transcription 
Suvorexant  [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-
(2H-1,2,3-triazol-2-yl)phenyl]methanone 
TEA  Tetraethylammonium (chloride) 
TM  Transmembrane helix 
TRPC (channel) Transient receptor potential (channel) of the canonical subfamily  
YFP  Yellow fluorescent protein 
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1. Introduction 
Cells must communicate with each other in order to support the functions of multicellular 
organisms. For efficient communication, cells need proteins called receptors. Receptors can be 
situated at the cell surface or inside the cell and they can bind signalling molecules, called ligands. 
Ligands can be, for instance, peptides, amino acids or fatty acids, and each receptor can only bind a 
receptor-specific ligand. If the bound ligand is an agonist, the receptor is activated and it can further 
activate specific intracellular signalling pathways. These pathways may be simple and 
straightforward or more complicated, including the involvement of second messengers or cross-
communication of different pathways. The pathway ultimately transduces the signal to targets, like 
ion channels or enzymes. After receiving the signal, the behaviour of the target changes, for 
instance ion channels are opened or enzymes are activated. 
 Cell communication is crucial throughout the lifespan of an organism. Cell signalling already 
occurs during fertilisation, when sperm cells must sense chemoattractants in order to reach the egg 
cell. In a developing embryo, stem cells communicate with each other to determine which cell type 
they will differentiate to. Altogether, cells are constantly receiving signals that determine whether 
the cell should survive, divide or die.  
 There would be no multicellular organisms on earth without cell communication. Cells 
constantly receive signals from each other and from the environment, and these signals are passed 
to target molecules through signalling pathways. Cell signalling research is not only important to 
help us understand the communication by natural signalling molecules, like hormones, but to also 
understand the signalling by exogenous molecules, like drugs. In order to better understand 
pathological processes, we need to be able to detect what occurs on the cellular level and to 
understand the language of the cell: cell signalling. 
2. Review of the literature 
2.1.  G-protein-coupled receptors 
G-protein-coupled receptors (GPCR) constitute the largest membrane receptor superfamily with 
more than 800 different genes. Members of the GPCR family span from hormone to sensory 
receptors and also include receptors, for instance, for neuropeptides, chemokines, lipid mediators, 
nucleotides, and calcium ions (Pierce et al., 2002). Thus GPCRs are responsible for the regulation 
of most of the physiological processes in our body (Rosenbaum et al., 2009). As GPCRs form the 
most extensively studied receptor group, they are also the most common target of therapeutic drugs 
(Pierce et al., 2002; Civelli et al., 2013). 
2.1.1. GPCR structure 
GPCR structure is characterised by seven transmembrane helices (TMs) that are linked by 
alternating intra- and extracellular loops. TMs are arranged as a closed “barrel” with TM7 adjoining 
TM1, a structure that is stabilised by hydrogen bonds and salt bridges (Ji et al., 1998). Thus, the 
TMs form the core of the receptor. Extracellular amino and intracellular carboxyl tails also 
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characterise the structure of GPCR. Amino and carboxyl tails and intra- and extracellular loops, the 
intracellular loop linking TM5 and TM6 in particular, are the most variable structures within the 
GPCR family (Ji et al., 1998; Kobilka, 2007). 
 The first crystal structure solved for a GPCR was of bovine rhodopsin, which was published 
in 2000 (Palczewski et al., 2000). The crystal structures of several other GPCRs have been solved 
since (see for instance Cherezov et al., 2007; Wu et al., 2010; Shimamura et al., 2011; Hanson et al., 
2012). For the GPCRs with still unknown crystal structure, parts of the structure, like the location of 
the ligand binding domain, can be predicted with mutagenesis studies, like site-directed 
mutagenesis (Kristiansen, 2004; Kobilka, 2007). Small organic agonists, like monoamines and 
odorants, seem to bind to the TMs of the GPCR, whereas peptide hormones and proteins utilise the 
amino terminal tail and extracellular sequences (Kobilka, 2007). The size of the ligand does not 
always correlate with the location of the binding site. For instance, glycoprotein hormones, 
glutamate, and Ca
2+
, despite of being of very different sizes, all bind to the amino terminal tail of 
their receptors.  
2.1.2. Signalling through GPCRs 
GPCRs are named according to the ability of the activated receptor to signal through coupling to a 
guanine nucleotide-binding protein (G-protein). These G-proteins are membrane-bound 
heterotrimeric proteins consisting of α, β, and γ subunits (Wess, 1997). When inactive, Gα subunit 
binds GDP. Ligand binding-triggered activation of the GPCR leads to coupling of the receptor with 
the G-protein and exchange of the Gα-bound GDP for GTP. That exchange leads to the dissociation 
of the G-protein from the receptor. Gα-GTP has decreased affinity for other G-protein subunits and 
thus a tight Gβγ complex is released from the Gα. Both the Gα subunit and the Gβγ complex signal 
by activating or inhibiting effectors, of which there is a large number. These putative effectors 
include, for instance, ion channels and enzymes that further regulate the production, release and 
degradation of intracellular second messengers and thereby amplify the signal (Simon et al., 1991; 
Pierce et al., 2002; Milligan and Kostenis, 2006). The GDP/GTP binding pocket of Gα has 
guanosine triphosphatase (GTPase) activity and it can hydrolyse the terminal phosphate of GTP 
(Wess, 1997; Wettschureck et al., 2004; Milligan and Kostenis, 2006). This hydrolysis leads to 
replacement of GTP with GDP and reassociation of the Gβγ complex with the Gα subunit, 
terminating the G-protein signalling. However, the intrinsic GTPase activity of the Gα subunit is 
not very pronounced, but is enhanced by other proteins (see, 2.1.5. Regulation of GPCRs). 
 G-protein subunits do not always dissociate, but instead the subunits can undergo 
rearrangement. These non-dissociable G-proteins are found, for instance, in mammalian, yeast and 
plant cells (Klein et al., 2000; Bunemann et al., 2003; Adjobo-Hermans et al., 2006). G-protein may 
also be precoupled to the receptor. This kind of precoupling is found for, at least, muscarinic, 
dopamine and adenosine receptors, and it may contribute to a more rapid regulation of the effector 
proteins after receptor activation (Nobles et al., 2005). 
 Even though heterotrimeric G-proteins function in the plasma membrane, near the GPCRs, 
they can also be found in the membranes of intracellular organelles. For instance, membranes of 
endoplasmic reticulum (ER), Golgi apparatus, and endosomes are shown to include G-proteins of 
the stimulatory and inhibitory classes (Gs and Gi, respectively) (Helms, 1995). Actually, it is 
confirmed that G-proteins are not constantly located in the plasma membrane, but instead they 
reside in these intracellular membranes from where they can shuttle to the plasma membrane 
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(Chisari et al., 2007). In addition, intracellular G-proteins have functions in membrane trafficking, 
endocytosis and secretion, like protein transport from Golgi to apical membranes or stimulation of 
exocytosis (Helms, 1995; Chisari et al., 2007). 
2.1.3. Alternative signalling pathways of GPCRs 
GPCRs are sometimes called seven transmembrane receptors, heptahelical receptors or serpentine 
receptors to underline the fact that their signalling is not limited to the heterotrimeric G-proteins. 
For instance, metabotropic glutamate receptor and type 1 angiotensin II receptor (AT1) use both G-
protein-dependent and -independent signalling (Heuss et al., 1999; Wei et al., 2003). It is suggested 
that G-protein-independent signalling of AT1 may activate an anti-apoptotic pathway in the heart 
(Rajagopal et al., 2005; Zhai et al., 2005). 
 How G-protein-independent signalling occurs remains partly unknown. Studies of G-protein-
independent signalling prove challenging because suitable controls for the effectiveness of G-
protein blocking are lacking (Heuss and Gerber, 2000). Some potential signalling mechanisms have 
been found, however, including one that involves G-protein-coupled receptor kinases (GRKs) and 
β-arrestin, which are described in more detail below (see, 2.1.5.3. GPCR kinases and arrestin) 
(Rajagopal et al., 2005). Another mechanism, which actually seems to be active in the case of AT1 
receptor, includes the Janus kinase (JAK) pathway (Ritter and Hall, 2009). Binding of angiotensin 
II to the AT1 receptor, and association of JAK with tyrosine protein phosphatase non-receptor type 
11, causes JAK association with the AT1 receptor. That promotes JAK phosphorylation and 
activation. JAK can further phosphorylate members of signal transducer and activator of 
transcription (STAT) family. STATs are transcription factors, which, once phosphorylated, dimerise 
and translocate into the cell nucleus, where they exert gene regulation to control cell growth. 
 Another special signalling feature of GPCRs originates from the fact that the receptors can 
have multiple conformations in the active (ligand bound) state (Kenakin, 2010). Each of these 
conformations can selectively interact with a different ligand. Different conformations of the 
receptor can eventually activate different signalling pathways. This phenomenon has multiple 
names like “biased agonism”, “functional selectivity”, “ligand-selective agonism” or “ligand-
induced selective signalling”. It could have potential use in selective pharmacology as drugs could 
be used to only activate the pathway of interest (Kenakin, 2012). 
 Sometimes GPCRs can signal in the absence of a ligand. These receptors are called 
constitutively active and their constant activity is caused by mutations (Parnot et al., 2002). GPCRs 
with constitutively active mutations adopt a structure of the active receptor, and thus they are able 
to couple with the G-protein. Opioid and β2-adrenergic receptors were one of the earliest GPCRs 
with detected constitutive activity (Cerione et al., 1984; Costa and Herz, 1989). However, now 
constitutively active mutants have been found for many other GPCRs as well, including, for 
instance, α1-adrenergic, rhodopsin, and muscarinic receptors (Cohen et al., 1992; Scheer et al., 
1996) (Spalding and Burstein, 2001). Constitutively active receptor mutants are associated with 
several disorders like night blindness, hyperthyroidism, and Leydig cell adenoma (Dryja et al., 
1993; Parma et al., 1993; Liu et al., 1999). 
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2.1.4. Classification of G-proteins 
Heterotrimeric G-proteins are classificated into four families according to the Gα subunits 
(Alexander et al., 2011). The families are Gαq, Gαs, Gαi, and Gα12, and they all contain multiple 
isoforms of α subunits with different structures, expression profiles and, partially, functions as well. 
Because of the high number of different Gα subunit isoforms, only the best known and the most 
studied isoforms of each G-protein family are described below. Figure 1 summarises the signalling 
pathways of each G-protein family.  
2.1.4.1. Gαq family 
Gα subunits of the Gαq family activate β isoforms of phospholipase C (PLCβ) (Neves et al., 2002). 
The Gβγ complex can also stimulate PLCβ, and thus its activation is not restricted to the G-proteins 
of the Gαq family (Rebecchi and Pentyala, 2000). PLC catalyses the hydrolysis of 
phosphatidylinositols, like phosphatidylinositol-4,5-bisphosphate (PIP2), to diacylglycerol (DAG) 
and inositol trisphosphate (IP3). PIP2 is not only a precursor of DAG and IP3 but also works as a 
cellular regulator on its own (Suh and Hille, 2005). PIP2 can, for instance, directly regulate several 
ion channels and participate in actin cytoskeleton remodelling, membrane targeting and vesicle 
trafficking (van den Bout and Divecha, 2009). The second messenger IP3 causes elevation of 
intracellular calcium in two different ways. It directly binds to IP3 receptors in the ER and activates 
the release of intracellularly stored calcium (Neves et al., 2002; Berridge, 2009). That indirectly 
activates store-operated calcium channels (SOCs) in the plasma membrane, which leads to calcium 
influx. DAG has multiple roles in the cell. It activates protein kinase C (PKC), which is involved in 
many cellular functions like receptor desensitisation, regulation of transcription and regulation of 
cell growth (Newton, 1995; Neves et al., 2002). DAG also activates some transient receptor 
potential (TRP) channels of the canonical subfamily (TRPC) most likely by direct binding to them 
(Soboloff et al., 2007; Kukkonen, 2011). As PKC is an inhibitor of most TRPC channels, DAG has 
a dual role in the regulation of these channels. In the Golgi apparatus, DAG is involved in vesicle 
budding (Kearns et al., 1997). 
 Another member of the Gαq family is Gα11. Gα11-coupled receptors are involved in mediating 
the effects of almost all vasoconstriction-causing hormones (Wettschureck et al., 2004). As vascular 
resistance is one of the factors determining blood pressure, reduction of the resistance could be one 
approach to be used in the treatment of arterial hypertension. Thus blocking the signalling of Gα11 
in smooth muscle cells could be an effective method to treat hypertension (Wettschureck et al., 
2004). 
 The remaining members of the Gαq family are Gα14- and Gα15/16-proteins. Gα15 is murine and 
Gα16 human homologue of the same protein (Simon et al., 1991). Gα14 is expressed primarily in 
stromal and epithelial cells whereas Gα15/16 is found in lymphocytes and myeloid cells. These 
members can also activate PLCβ, but as can be predicted from their differing tissue distribution, 
different members of Gαq family may have also some distinct functions. In vascular smooth muscle 
cells, Gαq and Gα14, but not Gα15, can activate caspase 3 to cause cell death (Peavy et al., 2005). 
The role of Gα15 is still partly unclear, but it may be involved, for instance, in hematopoietic cell 
growth and differentiation (Giannone et al., 2010). Gα16 is reported to have an ability to activate the 
transcription factor STAT3, which was earlier thought to be controlled via cytokine receptors (Wu 
15 
 
et al., 2003). However, as mentioned above, now it is known that also G-protein-independent 
signalling of the angiotensin II receptor potentiates STAT signalling (Ritter and Hall, 2009).  
2.1.4.2. Gαs family 
Gs subunits stimulate adenylyl cyclase (AC) which catalyses the conversion of ATP to cAMP 
(Pierce et al., 2002; Wettschureck et al., 2004; Zhang and Xie, 2012). Constant stimulation of AC 
activity can be achieved with cholera toxin, which catalyses ADP-ribosylation (and activation) of 
Gαs (Milligan and Kostenis, 2006). cAMP acts as a second messenger in the cell via protein kinase 
A (PKA) and other effectors (Pierce et al., 2002; Wettschureck et al., 2004; Zhang and Xie, 2012). 
cAMP has a ubiquitous role in many physiological functions, and homozygous Gαs knockout mice 
die early under embryonic development (Yu et al., 2001; Wettschureck et al., 2004). 
 Another G-protein belonging to the Gαs subfamily is Golf. Like Gαs, Gαolf also has the ability 
to activate AC (Offermanns and Simon, 1998). Gαolf is mainly expressed in specialised sensory 
cells, especially in olfactory epithelium (Simon et al., 1991). However, it is also found in striatum 
where it transduces dopamine receptor signals (Zhuang et al., 2000). Homozygous Gαolf knockout 
mice cannot smell odours, suggesting that Gαolf is needed for olfactory signal transduction 
(Belluscio et al., 1998).   
2.1.4.3. Gαi family 
In contrast to Gs, Gi inhibits the activity of AC (Taussig et al., 1993). However, all members of 
the Gαi family are not involved in AC inhibition, and there are multiple AC isoforms, which are not 
all affected by Gi (Steegborn et al., 2005; Sadana and Dessauer, 2009). Gβγ signalling to, for 
instance, AC and G-protein-coupled inwardly rectifying potassium (GIRK) channels is thought to 
mainly originate from Gi-proteins (Ikeda et al., 2002). Gβγ of the Gi-protein also stimulates PLCβ 
(Neves et al., 2002); however Gαq is first required to preactivate it. This kind of crosstalk between 
different G-protein subtypes may have an important role in the refinement of signals (Chan et al., 
2000). In addition to the crosstalk between Gi- and Gq-proteins, a Gαq-independent, Ca
2+
 influx-
mediated pathway for the Gi-protein-mediated stimulation of PLC, is speculated (Murthy et al., 
2004). 
 Go- and Gz-proteins are also members of the Gαi family. As Go is the most abundant G-protein 
expressed in the brain, it is also the main source of the brain’s Gβγ, which has an important role, for 
instance, in the activation of GIRK channels (Exner et al., 1999; Khan et al., 2013). Opening of the 
GIRK channels causes efflux of potassium ions, which leads to membrane hyperpolarisation: the 
mechanism used to reduce neuronal excitability and heart rate. One notable effect via GIRK 
channels is by opioids (Ikeda et al., 2002). A number of receptors, including α2 adrenergic, D2 
dopamine and M2/M4 muscarinic receptors, can couple to Go- and Gi-proteins. Functions of Gαo are 
still partly unclear but they seem to differ from the functions of the Gαi. It is known that Go-coupled 
muscarinic acetylcholine receptors mediate parasympathetic regulation of the heart (Wettschureck 
et al., 2004). Gαo has also been shown to have a role in the prevention of PKA translocation into the 
nuclear compartment (Ghil et al., 2006). 
 The function of the primarily neuronal Gαz, has not been fully identified; however, it is 
known to inhibit AC. Gαz has exceptionally slow GTPase activity. There is, however, a Gαz-
specific GTPase-activating protein (GAP) expressed together with Gz-protein, and it is partly 
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responsible for the hydrolysis of the GTP (Simon et al., 1991; Fields, 1998; Wettschureck et al., 
2004). 
 Signalling of Gi-coupled GPCRs can be inhibited with pertussis toxin. Pertussis toxin 
catalyses ADP-ribosylation of all Gαi members, except Gαz, by preventing the interaction between 
G-protein and the GPCR. Thus Gαi remains in the inactive GDP-bound state (Milligan and 
Kostenis, 2006). However, there is also evidence for ADP-ribosylation-independent actions of 
pertussis toxin (Mangmool and Kurose, 2011). 
2.1.4.4. Gα12 family 
The Gα12 subfamily contains two members called G12 and G13. GPCRs known to couple to G12- and 
G13-proteins include receptors for acetylcholine, serotonin, vasopressin and dopamine, just to name 
some (Siehler, 2009). Gα12 and Gα13 can activate guanine nucleotide exchange factors (GEFs) 
which in turn activate Rho family G-proteins (Aittaleb et al., 2010). Rho family members are 
monomeric G-proteins and, like trimeric G-proteins, they also cycle between GTP-bound active and 
GDP-bound inactive states (Siehler, 2009). In the signalling of Gα12 and Gα13, RhoGEFs, like p115-
RhoGEF, homology-RhoGEF and leukemia-associated RhoGEF, promote enrichment of the GTP-
bound form of RhoA, which regulates cytoskeleton proteins and can indirectly regulate the number 
of actin and myosin fibres. Overexpression of Gα12 and Gα13 is involved, for instance, in cancer and 
cardiovascular diseases (Siehler, 2009; Kozasa et al., 2011). 
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Figure 1. Simplified picture of the main signalling pathways of the four G-protein families. Arrows 
indicate activation and blunt end arrows inhibition. AC, adenylyl cyclase; cAMP, cyclic adenosine 
monophosphate; COOH, carboxyl-terminus of the receptor; DAG, diacylglycerol; GEF, guanine 
nucleotide exchange factor; GIRK, G-protein-coupled inwardly rectifying potassium; GPCR, G-
protein-coupled receptor; IP3, inositol triphosphate; NH2, amino-terminus of the receptor; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PKA, protein kinase A; PKC, protein kinase C; PLCβ, β 
isoform of phospholipase C; TRPC, transient receptor potential (channel) of the canonical 
subfamily. 
 
2.1.5. Regulation of GPCRs 
GPCRs are tightly regulated in both the short- and long-term manner throughout their life cycle (De 
Vries et al., 2000). Long-term regulation includes regulation via gene transcription, translation and 
post-translational modifications, like phosphorylation, palmitoylation or acetylation. Trafficking of 
the synthesised receptor to the cell membrane is also highly regulated. On the cell surface, the 
receptor interacts with short-term regulating proteins, which may, for instance, modulate receptor 
oligomerisation or change the ligand affinity or -selectivity of the receptor (De Vries et al., 2000; 
Millar and Newton, 2010). 
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2.1.5.1. Dimerisation and oligomerisation 
It is speculated that GPCRs need to form homo- or heterodimers or -oligomers during their 
biosynthesis in the ER to be expressed on the cell surface (Hill, 2006). Homo- or hetero-
oligomerisation also offers new possibilities for GPCR regulation. Some receptors activate certain 
signal pathways as homodimers but will show different signalling as heterodimers. This 
phenomenon is called “heteromer-directed signalling specificity” (Millar and Newton, 2010; Zhang 
and Xie, 2012). This has been found to occur with dopamine D1 and D2 receptors that couple to Gs- 
and Gi-proteins, respectively, as monomers but to Gq as heterodimers (Lee et al., 2004). Heteromer-
directed signalling specificity is also believed to be involved in dysfunction of the receptor in 
certain pathological states, and thus dimerisation-affecting drugs could have a therapeutic use 
(Zhang and Xie, 2012). 
2.1.5.2. Regulators of G-protein signalling 
GTPase-activating (or -accelerating) proteins (GAPs) promote the hydrolysis of Gα-bound GTP to 
GDP and thus termination of the G-protein signalling. Regulators of G-protein signalling (RGSs) 
are proteins working as GAPs at least in the signalling of G-proteins of Gαq, Gαi, and Gα12 families, 
through binding to their Gα subunits (De Vries et al., 2000; Zhong and Neubig, 2001; Siehler, 2009; 
Magalhaes et al., 2012). In addition to binding to Gα subunit, direct interaction between RGS 
proteins and receptors has been observed (Zhong and Neubig, 2001). Binding of any RGS to G-
proteins of Gαs family has not been found; actually, Asp229 of Gαs has been shown to structurally 
prevent the interaction (Natochin and Artemyev, 1998). However, type V AC, stimulated by Gαs, 
has been shown to enhance the GTPase activity of Gs and it may thus work as a GAP for Gαs 
(Scholich et al., 1999). Similarly, an effector of Gq signalling, PLCβ, works as GAP by promoting 
the hydrolysis of Gαq-bound GTP (Biddlecome et al., 1996). In addition to the GAP activity, RGS 
proteins also have two other ways to turn off signalling of G-proteins. Firstly, they can physically 
prevent binding of effectors, like PLCβ, to G-proteins. Secondly, after GTP hydrolysis, they can 
increase the affinity of Gα subunits for the Gβγ complex and thereby enhance the formation of the 
inactive heterotrimer (De Vries et al., 2000). Independent of G-proteins, RGS proteins can target 
protein kinase A and regulate GIRK currents. In addition to negative regulation of signalling, also 
positive, activity-enhancing functions of RGSs have been shown for RGS4, which can potentiate 
α2-adrenergic receptor-stimulated GTPγS binding to the α-subunit of a G-protein (Zhong and 
Neubig, 2001).  
 There are more than 20 different RGS proteins identified in mammals. All of these proteins 
contain a conserved RGS box region, which is needed for their GAP activity. Many of the RGS 
proteins have membrane-targeting signal sequence in their N-terminus to localise them near their 
targets. RGS proteins also have other domains that vary between different members of the RGS 
family and these are needed to link RGS proteins to other signalling pathways and proteins (De 
Vries et al., 2000). These extra domains are involved, for instance, in the regulation of protein 
localisation and intracellular trafficking (Zhong and Neubig, 2001; Magalhaes et al., 2012). 
2.1.5.3. GPCR kinases and arrestin 
The first proteins found to interact with GPCRs and to regulate uncoupling of GPCRs from G-
proteins were GPCR kinases (GRKs) and arrestins. GRKs are composed of three functional 
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domains: the amino-terminal domain, which is homologous to RGS proteins; the central catalytic 
domain; and the carboxyl-terminal, membrane-targeting domain. GRKs phosphorylate serine and 
threonine residues in the third intracellular loop and carboxyl-terminal domain of activated GPCRs 
and thus promote desensitisation of GPCRs (Hill, 2006; Magalhaes et al., 2012). GRKs can also 
mediate phosphorylation-independent desensitisation of GPCR. For instance, GRK2 and GRK3 can 
mediate uncoupling of Gα11 from the receptor. GRKs also regulate endocytosis of GPCRs to allow 
their dephosphorylation and resensitisation (Magalhaes et al., 2012). 
 For many GPCRs, GRK-mediated phosphorylation alone is insufficient to cause 
desensitisation of the receptor. Instead, binding of β-arrestin proteins, together with GRK-mediated 
phosphorylation, is needed for full desensitisation and endocytosis of the receptor (Magalhaes et al., 
2012). Some GPCRs bind β-arrestin with low affinity; they are dephosphorylated, resensitised and 
rapidly recycled back to the plasma membrane. Receptors that bind β-arrestins with high affinity are 
internalised as tight receptor-β-arrestin-complexes to endosomes. Their recycling to plasma 
membrane happens very slowly or not at all (Magalhaes et al., 2012). 
 β-arrestins were first identified for their ability to desensitise and thus reduce GPCR 
signalling (Lefkowitz, 1998). However, β-arrestins are now also known, for instance, as endocytotic 
adaptor proteins, which target the receptors for clathrin-mediated endocytosis, and as mediators of 
G-protein independent signalling (Lefkowitz and Shenoy, 2005; Shukla et al., 2011). 
2.1.5.4. Receptor desensitisation 
Prolonged binding of an agonist to a GPCR may not cause continued response. Instead it can lead to 
desensitisation of the receptor (Hill, 2006). Desensitisation is most extensively studied for the β2-
adrenoceptor, and its desensitisation can be divided into agonist occupancy-dependent 
desensitisation and PKA-dependent desensitisation (Benovic et al., 1985; Hill, 2006). A weak 
stimulation of the β2-adrenoceptor stimulates AC and thus increases the level of cAMP, which 
activates PKA (Hill, 2006). PKA mediates desensitisation of the β2-adrenoceptor through 
phosphorylation but it can only cause partial uncoupling of the receptor from its G-protein. Agonist-
dependent desensitisation may be used to achieve stronger desensitisation. In high agonist 
occupancy, GRKs can mediate phosphorylation of the receptor, eventually preventing the 
interaction between the receptor and the G-protein, and cause receptor internalisation (Hill, 2006). 
 Sometimes receptor phosphorylation works as a molecular switch, which exchanges the 
coupling of the receptor between different G-protein subtypes. For instance, PKA-dependent 
desensitisation of β2-adrenoceptor has been shown to switch the coupling of the receptor from Gs to 
Gi (Daaka et al., 1997).  
2.1.5.5. Receptor activity-modifying proteins 
Receptor activity-modifying proteins 1 and 2 (RAMP1 and RAMP2, respectively) regulate the 
expression of receptors at the cell surface and modulate the structure of the receptors resulting in 
altered ligand specificity (Hill, 2006; Magalhaes et al., 2012). RAMPs were first found to modulate 
the activity and pharmacology of calcitonin receptor and calcitonin receptor-like receptor of the 
secretin family GPCRs (McLatchie et al., 1998). Some studies have revealed, however, that 
RAMPs may also be involved in the regulation of other receptor types. At least some receptors of 
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the glutamate family are regulated that way (for more information of secretin and glutamate 
families, see below)  (Magalhaes et al., 2012). 
2.1.6. Classification of GPCRs 
The GPCR superfamily can be classified into five different families based on their homology in 
sequence, structure and phylogeny. The families are rhodopsin, secretin, glutamate, adhesion, and 
frizzled/taste2 family (Lagerstrom and Schioth, 2008). 
 The rhodopsin family, with its approximately 670 members, is the largest of these families 
and it also contains the highest number of pharmacologically targeted receptors (Pierce et al., 2002; 
Kobilka, 2007; Lagerstrom and Schioth, 2008; Rosenbaum et al., 2009). Receptors of the rhodopsin 
family can be further divided into α, β, γ, and δ groups (Lagerstrom and Schioth, 2008). The α 
group contains many important drug targets like histamine, dopamine and adrenergic receptors. The 
β group contains peptide-binding receptors, like receptor for gonadotropin-releasing hormone. Even 
though this group includes some important drug targets, peptide receptors present challenges 
regarding drug discovery given that peptide ligands are large and flexible, and thus the molecular 
features, which are important for the optimal interaction with a receptor, are difficult to identify. 
Smaller γ and δ groups include receptor for mediators like opioids and odorants, respectively 
(Lagerstrom and Schioth, 2008). 
 The secretin family contains receptors for peptide hormones, like the gastrointestinal peptide 
hormone secretin, glucagon, growth hormone-releasing hormone and corticotropin-releasing 
hormone (Lagerstrom and Schioth, 2008). All members of this family signal through coupling to Gs 
and thus mediate increase of intracellular cAMP (Pierce et al., 2002). In addition, all the receptors 
of the family have a similar extracellular hormone-binding domain and conserved cysteine residues 
in first and second extracellular loops (Lagerstrom and Schioth, 2008).  
 The relatively small glutamate family contains receptors, for instance, for glutamate, -
aminobutyric acid (GABA), Ca
2+
, and sweet and umami tastes. All receptors of this family have a 
large amino-terminal tail, which is needed for ligand binding (Pierce et al., 2002; Lagerstrom and 
Schioth, 2008). 
 All adhesion family members show an extended amino terminus, which is thought to be 
required for cell‒cell contact (Millar and Newton, 2010). Members of the adhesion family share 
homology in sequence with the members of secretin family but are very different with respect to the 
N-terminal domain (Lagerstrom and Schioth, 2008). Most of the receptors of the adhesion family 
remain orphan, meaning that they do not have known endogenous ligands (Millar and Newton, 
2010). 
 The frizzled/taste2 family can be further divided into groups of frizzled, smoothened, and 
taste2 receptors (Lagerstrom and Schioth, 2008). The most studied ligands of frizzled receptors are 
Wnt glycoproteins. Frizzled receptors play an important role in the regulation of cellular polarity, 
embryonic development, synapse formation and regulation of proliferation (Huang and Klein, 
2004). Smoothened receptors are structurally related to frizzled receptors. They are involved in 
many developmental processes in the Hedgehog signalling pathway. Mutations in both frizzled and 
smoothened receptors are detected in cancers and thus drugs targeting these receptors could have 
therapeutic use (Taipale et al., 2000; Nagayama et al., 2005; Lagerstrom and Schioth, 2008). 
Taste2-family receptors bind bitter-tasting compounds, like cycloheximide (Chandrashekar et al., 
2000). A single taste receptor cell expresses multiple receptors of taste2 group and can thus sense 
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many structurally unrelated, bitter-tasting compounds; however, many receptors of the taste2 family 
are still orphan (Lagerstrom and Schioth, 2008). 
Most of the putative GPCRs are identified based on the homology of their DNA sequences to 
sequences of known GPCRs and/or phylogenetic algorithms. Receptors identified this way may not 
have an endogenous ligand and they are called orphan receptors (Civelli et al., 2013). It is good to 
keep in mind that not all of the putative receptors identified finally couple to a G-protein. Still, 
about 25% of suggested human GPCRs remain orphan (Summers, 2012). As GPCRs have potential 
as drug targets, however, they are the most studied receptor family for pharmaceutical intervention. 
This will finally lead to discovery of ligands for orphan receptor, a process called deorphanisation 
(Wilson et al., 1998; Kobilka, 2007). The rhodopsin family includes the highest number of orphan 
receptors (currently 67) (Civelli et al., 2013).   
2.2. GPCRs as drug target 
There are several reasons why GPCRs are one of the most studied drug targets in the 
pharmaceutical industry. One central reason is that GPCRs constitute one of the largest gene 
families and they regulate many physiological functions. GPCRs also have a long history in drug 
discovery and they are already targets for many drugs world-wide. Actually, GPCRs are targets for 
more than 30% of all currently available drugs, like opioid analgesics, antihistamines, 
antidepressants and many cardiovascular drugs (Harrison and Traynor, 2003; Hill, 2006; Insel et al., 
2012). 
 Drug discovery is a multidisciplinary process involving target identification and validation, 
identification and development of candidate drugs, preclinical safety and efficacy studies and 
finally clinical studies (Hughes et al., 2011). The whole process can take up to 15 years and only a 
very small number of candidate drugs are finally registered. The studies reported here mostly touch 
upon ligand development and methodology for ligand identification/screening. The approaches 
utilised for these in GPCR research will be outlined here. 
 Several different approaches may be used for ligand development. A classical method, 
utilised for instance in -adrenoceptor antagonist development, is based on pharmacophore 
identification (Pitha et al., 1983). Pharmacophore means the molecular features of a chemical 
compound needed for the optimal interaction with the target of the compound and to cause its 
biological response (Yang, 2010). When several compounds, all of which bind to the same receptor, 
are studied, a pharmacophore can be identified. After identification, the pharmacophore is verified 
and utilised then to identify and develop novel ligands, for instance by actual or virtual means. 
 Chemical synthesis can be used to produce large sets of ligands to refine the binding affinity 
and selectivity and possibly even distinguish agonists and antagonists (Heckmann and Kessler, 
2007). Other approaches may have to be used when there is no known natural ligand, the natural 
ligand is too complex or otherwise unsuitable, or when an allosteric binding site is the target. One 
such approach is to define putative ligands based on the receptor model (Schneider and Fechner, 
2005). Models are often based on direct crystal structures, homology models of such and/or receptor 
mutagenesis studies (Kobilka, 2007). Another method would be to randomly screen with a more or 
less diverse library. 
 The technology used for drug screening is not a trivial choice. Many different methods are 
available with distinct advantages and disadvantages and costs. From a high-throughput 
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perspective, an ideal assay would be simple, homogeneous, reproducible, nonradioactive and easily 
adapted for robotics and microtiter plate format, and have a high signal-to-noise ratio (Thomsen et 
al., 2005). Methods used to screen ligands can be roughly divided into binding and functional 
assays. Sometimes, like in the case of biased ligands, several different assays utilising different 
pathways may need to be performed and the results combined to obtain enough information from a 
certain drug molecule (Kenakin and Christopoulos, 2013). 
2.2.1. Binding assays 
Historically, the first method used to study GPCR-binding compounds was receptor binding assay 
(Lefkowitz et al., 1970). While ligand screening often utilises equilibrium binding, kinetic 
measurements are also possible; however, only the equilibrium assays will be described here. 
Binding assay typically requires the use of a radioactive ligand, which has known binding 
parameters to the receptor of interest (Zhang and Xie, 2012). Radioligand is exposed to competition 
with the non-labelled ligands to be screened, and thus the inhibitory constant, Ki, for each ligand 
can be calculated. Fluorescence may be used as an alternative marking for the radioactivity (Cottet 
et al., 2011). This binding assay is usually rather inexpensive, but there are problems with it too. It 
requires a known ligand with suitable properties (Zhang and Xie, 2012). Furthermore, the method is 
not homogeneous as it requires the separation of bound and free ligand, which is usually achieved 
by filtration. 
 In homogenous binding assays, there is no need to separate or wash the unbound ligands  
before the measurement, and thus they are suitable for automation (de Jong et al., 2005). 
Homogenous assays can be based, for instance, on fluorescence polarisation, or fluorescence/ 
Förster resonance energy transfer (FRET) between a labelled receptor and a labelled ligand (Allen 
et al., 2000; de Jong et al., 2005). These assays may be more suitable for particular systems and not 
others due to either methodological obstacles or high cost. 
2.2.2. Functional assays 
Binding assays only offer information regarding the most primary part of the ligand/receptor 
interaction, the binding itself. To further characterise the response and to study functional properties 
of the ligand, functional assays are needed (Zhang and Xie, 2012). Functional assays are 
particularly important to study the properties of agonists, and to distinguish agonist from antagonist. 
Assays include measurement of G-protein activation or G-protein-mediated events like second 
messenger generation or gene reporter activation (Chen et al., 2012; Zhang and Xie, 2012). 
2.2.2.1. [35S]GTPγS binding assay 
GTPγS binding assay is used to determine the activation of GPCR by measuring the binding of 
GTP to G-protein (Harrison and Traynor, 2003; Zhang and Xie, 2012). Non-hydrolysable analogue 
of GTP, [
35S]GTPγS, is used to radioactively label G-proteins as a measure of receptor activation. 
Being non-hydrolysable, [
35S]GTPγS accumulates in the Gα, and as it remains membrane-bound, 
the membrane preparation can be filtrated and radioactivity from the filter counted, as is done for 
the radioactive receptor binding assay (Harrison and Traynor, 2003). 
 The method is most widely used with Gi-coupled GPCRs as these G-proteins are the most 
abundant in many cell types and also their GDP to GTP exchange rate is faster than for other 
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subtypes (Harrison and Traynor, 2003; Zhang and Xie, 2012). The advantage of this method is that 
it measures the receptor-mediated response early after receptor activation and measurements are not 
subjected to amplification or other modulation that occurs in downstream signalling. That is why 
the method can also be used to make a difference between full, partial, and inverse agonist, neutral 
antagonist, and allosteric regulator. On the other hand, lack of amplification by downstream 
signalling usually leads to a low signal-to-noise ratio (Zhang and Xie, 2012). There are also non-
radioactive GTP analogs that may be used in the same way (Frang et al., 2003). 
2.2.2.2. Second messenger assays 
GPCR signalling involves many quite easily detectable second messengers. The most widely used 
assays detect changes in the cellular levels of cAMP, IP3, or Ca
2+
. Calcium
 
assays are very popular 
in GPCR drug screening because of the good availability of Ca
2+
-binding fluorescent dyes, like 
Fluo-3 and Fluo-4 (Thomsen et al., 2005). Elevation of intracellular Ca
2+
 in cells labelled with these 
dyes can be easily detected with a fluorescence plate readers, like FLIPR. In addition to the 
fluorescent dyes, there are also some luminescence-based dyes, like the jellyfish photoprotein 
aequorin (Rudolf et al., 2003). Another reason for the popularity of the calcium assay format is that 
it can be used to study GPCRs coupling to several G-protein isoforms. Even though receptors 
coupling to Gq most readily elevate Ca
2+
, calcium assays are not restricted to these receptors only. 
Gα16, a member of the Gαq-family and thus an inducer of calcium signalling, can recognise and 
couple many receptors, which normally couple to Gs- or Gi-proteins (Milligan et al., 1996; Thomsen 
et al., 2005). Coexpression of Gα16 has been used, for instance, in coupling of β2 adrenergic and M2 
muscarinic receptors to calcium signalling (Offermanns and Simon, 1995). Chimaeric Gq/11 or 
Gα16-proteins, like Gα16/z, can also be used to couple a wide range of receptors to calcium signalling 
(Milligan and Rees, 1999; Liu et al., 2003a). These approaches allow a wider use of the calcium 
assay. Still, there are some limitations in this assay format also. Slowly binding agonists are less 
suitable for the calcium assays as the Ca
2+ 
response occurs rapidly and the negative feedback by IP3 
degradation and Ca
2+
 pumping are quickly turned on (Thomsen et al., 2005; Chen et al., 2012; 
Zhang and Xie, 2012). 
 IP3 is rapidly hydrolysed into the bisphosphate, monophosphate, and finally to free inositol 
(Berridge, 2009). Treating the cells with Li
+
 inhibits inositol monophosphatase, the final enzyme of 
this cascade, and thus enables accumulation of IPs, IP1 in particular. There are radiometric, like 
3
H-
inositol-based, and non-radiometric, like fluorescent-based methods available to detect IP 
accumulation (Thomsen et al., 2005). Sometimes several methods have emerged to provide better 
assay formats for the HTS. For instance, scintillation proximity assay (SPA) has been combined 
with immobilised metal ion affinity chromatography, resulting in a fast and simple assay format for 
96-well plates (Liu et al., 2003b). Slow kinetics of IP1 accumulation makes it possible to use the 
method for slow-binding GPCR ligands (Chen et al., 2012; Zhang and Xie, 2012). 
 Accumulation of cAMP is studied with assay formats very similar to assays used to study 
accumulation of IP. Activated GPCRs coupled to Gs and Gi can stimulate or inhibit, respectively, 
AC, which catalyses the conversion of ATP to cAMP (Hadcock et al., 1990). Several cAMP assay 
formats are homogenous, and the detection is based, for instance, on radioactivity, luminescence, or 
fluorescence (Gabriel et al., 2003; Williams, 2004; Thomsen et al., 2005). For instance, 
accumulation of [
125
I]-labelled cAMP can be directly detected with the SPA, once the label comes 
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into close proximity with the scintillant surface of the SPA plates (Williams, 2004). One non-
radiometric alternative for studying cAMP accumulation is the use of ruthenium derivate-tagged 
cAMP, which is bound to special plates with anti-cAMP-antibody. After chemical and electrical 
stimulation, a light signal can be observed (Williams, 2004). Whichever assay format is used, 
cAMP hydrolysis by cyclic nucleotide phosphodiesterases usually has to be inhibited with 
phosphodiesterase inhibitor (Williams, 2004). In addition, an exogenous AC stimulus, usually 
forskolin, must be present when the inhibition of AC is measured (GPCRs coupling to Gi) (Seamon 
et al., 1981). 
2.2.2.3. Gene reporter assays 
Activated GPCRs regulate gene transcription of various genes via response elements for second 
messengers (Cheng et al., 2010). In reporter assays, these response elements are utilised to regulate 
expression of reporter proteins. Reporter proteins are usually enzymes linked with suitable 
substrates to colour, fluorescence or luminescence production like alkaline phosphatase, β-
galactosidase, luciferase or green fluorescent protein (Zhang and Xie, 2012). Especially firefly 
luciferase is widely used as a reporter because of its sensitivity, wide linear range, stability and 
persistent response (Fan and Wood, 2007). Easy-to-set-up reporter assays are also popular in high-
throughput screening (HTS) even though there are some concerns. The assays require long 
incubation times, and because signal is measured distal from the receptor activation, false positive 
results may occur. False results may also arise, for instance, from the interaction between studied 
chemical and the reporter protein or with protein synthesis machinery (Fan and Wood, 2007; Cheng 
et al., 2010; Zhang and Xie, 2012).  
2.2.2.4. In silico drug discovery 
The methods described above can be used for HTS. However, with constant improvement of 
computational methods, HTS can be more easily complemented with in silico screening. Such an 
approach can save both money and time as the number of experimentally tested compounds 
decreases, and compounds found with in silico screening have higher probability to also work in 
experimental approaches (Becker et al., 2004; Zhang and Xie, 2012). 
 Two in silico screening methods, named structure-based and ligand-based methods, are 
applied in GPCR drug discovery. Structure-based screening method requires a model of the 
structure of the target receptor (Zhang and Xie, 2012). The structure can be determined 
experimentally or with homological modelling (Shoichet and Kobilka, 2012). During the past few 
years, crystal structures of several GPCRs have been solved, which has improved homology-based 
models (Zhang and Xie, 2012). Screening is done so that the receptor structure and a library of 
molecules of interest are fitted together in a docking program. Hits are further tested, for instance, 
for their ability to compete with native ligands and for concentration-response relationships 
(Shoichet and Kobilka, 2012). 
 When the receptor structure is not available, as is the case for most GPCRs, ligand-based drug 
discovery can be used for in silico screening (Zhang and Xie, 2012). This method attempts to find 
new ligands through comparing their similarity on known ligands (Hessler et al., 2005). Ligand-
based screening is usually combined with other methods to obtain sufficient information about 
biological activity of the hit compounds (Gruber et al., 2010; Zhang and Xie, 2012).
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2.2.3. G-protein-independent functional assays 
There are some G-protein-independent methods developed to study GPCRs. These methods offer 
the advantage to also study receptors with unknown signalling pathways, given that no information 
regarding G-protein subtype is needed. That is why they may be more suitable for deorphanisation 
of GPCRs (Zhang and Xie, 2012). 
2.2.3.1. Receptor internalisation assays 
High-content screening (HCS) is a method that combines fluorescence microscopy with automated 
image analysis (Bickle, 2010). Different kinds of HCS systems can be used to study GPCR 
internalisation. As described earlier (see, 2.1.5.3. GPCR kinases and arrestin), GRKs and β-
arrestin regulate GPCR desensitisation and endocytosis. This receptor internalisation process can be 
followed with a fluorophore-labelled ligand or an antibody, which is directed, for instance, against 
the extracellular domain of the receptor. The receptor can also be tagged with a fluorescent protein, 
like green fluorescent protein (GFP) (Zhang and Xie, 2012). When using fluorophore-labelled 
protein, no fluorescent dyes or secondary substrates are needed (Chen et al., 2012). 
 HCS has the advantage of being independent of associated G-protein subtype and signalling 
pathways, and thus it is a suitable method to deorphanise GPCRs. With the use of multiple 
fluorophores, several parameters can be detected simultaneously from one cell. Disadvantages are 
the high price of instruments, long incubation times and the fact that some receptors do not show 
much internalisation (Chen et al., 2012; Zhang and Xie, 2012). In addition, internalisation does not 
necessarily correlate with other signalling (Kenakin, 2013).  
2.2.3.2. β-arrestin recruitment assays 
In addition to HCS, there are also other β-arrestin-recruitment assays available. One of them is 
bioluminescence resonance energy transfer (BRET) (Zhang and Xie, 2012). BRET is based on 
energy transfer between Renilla luciferase-tagged protein, β-arrestin in this case, and receptor 
tagged with mutant variant of GFP, like yellow fluorescent protein (YFP) (Xu et al., 1999; Zhang 
and Xie, 2012). When these two tags come close together, bioluminescence emitted in Renilla 
luciferase excites YFP, which emits a detectable signal. BRET is calculated as the ratio of the 
emissions of Renilla luciferase and YFP. Although BRET is a suitable method for many GPCRs, it 
also has disadvantages. The studied receptors need to be labelled with a fluorophore (Zhang and 
Xie, 2012). Also, the responses are relatively small. In addition to BRET, there are also some β-
arrestin recruitment assay kits commercially available. Detection in these kits is based on 
stimulation of reporter gene activity or chemiluminescent signal (Zhang and Xie, 2012). For 
instance, in the PathHunter enzyme complementation assay by DiscovereX, β-arrestin is linked with 
N-terminally truncated β-galactosidase while the GPCR of interest is tagged with this deleted part 
of the β-galactosidase (Olson and Eglen, 2007). Upon GPCR interaction with the β-arrestin, these 
two parts of the β-galactosidase come together activating the enzyme and generating a 
chemiluminescent signal upon exposure to the substrate (Zhang and Xie, 2012). 
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2.2.3.3. Label-free cellular assays 
Ligandreceptor binding assays and functional assays described above are the main cellular assays 
used in drug discovery for GPCRs. During the past few years, however, new label-free cellular 
technology has become a competitor for traditional assays. Label-free assays are based on 
biosensors that convert the ligand binding-induced signals into quantifiable responses (Fang, 2011; 
Chen et al., 2012; Zhang and Xie, 2012). Detection can be based, for instance, on optical, electrical 
or magnetic signal (Daniels and Pourmand, 2007; Dey and Goswami, 2011; Colombo et al., 2012). 
Biosensors can also detect changes in cellular properties like adhesion and proliferation (Zhang and 
Xie, 2012). 
 Dynamic mass redistribution optical biosensor and impedance electric biosensor are the two 
most widely used biosensors (Chen et al., 2012). Receptor signalling often includes, for instance, 
protein trafficking or changes in the cell adhesion or morphology, which all lead to dynamic mass 
redistribution. In the optical biosensor-based assay, biosensors simply detect the changes in the 
mass distribution (Fang, 2011). Although the method was initially intended for binding assays, it 
has also been successfully used in cell morphological and GPCR signalling studies. Electric 
biosensors can measure impedance, which is considered to be a sum of cellular events (Fang, 2011; 
Zhang and Xie, 2012). 
 As already mentioned, biosensors offer high sensitivity and enable detection of several 
cellular events (Fang, 2011); however, they also have some disadvantages. Their high price limits 
broad applications. In addition, false positive or negative results can occur (Anderson et al., 2000; 
Cooper, 2002). 
 Regarding biosensors, another label-free cellular assay is based on changes in cell phenotype, 
particularly in aggregation of melanosomes in melanophores after changes in the activity of AC and 
PLCβ (Graminski et al., 1993). Aggregation and deconcentration of melanosomes can be seen as 
light to dark changes in cells and this can be detected with a proper imaging and processing 
instrument. Difficulties persist, however, in melanophore technology when determining precise 
structure-activity relationships. Thus the method is not well suited for drug screening (Chen et al., 
2012). 
2.3. Orexin/hypocretin 
In January 1998, Luis de Lecea, Greg Sutcliffe and their co-workers published a study about 
hypothalamus-specific mRNA that encodes peptides, which they suggested to work as 
neurotransmitters in the central nervous system (CNS) (de Lecea et al., 1998). These hypothalamus-
produced peptides showed amino acid sequence similarity with the incretin hormone family and 
thus they were named hypocretins (hypothalamic member of incretin family). At that time, the 
physiological functions of hypocretins were only guessed, based on the comparison with other 
hypothalamic-produced neuropeptides. Productions of hypocretin and melanin-concentrating 
hormone, which is a promoter of food consumption, were mapped to the same area, and thus 
hypocretins were also speculated to regulate appetite. 
 Only a month after publication of this study, Masashi Yanagisawa and co-workers published a 
study about hypothalamus-specific mRNA that encodes two novel neuropeptides, both derived from 
the same precursor (Sakurai et al., 1998). They found that these neuropeptides bind to two orphan 
GPCRs and that they have an ability to stimulate food consumption in rats. Thus these 
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neuropeptides were termed orexins after the Greek word orexis, which means appetite. Two orexin 
peptides were called orexin-A and -B. Orphan receptors were named OX1 and OX2 receptors. 
 Now, 15 years later, there are thousands of research publications about orexins, and only 
between the years 2006 and 2010, there were more than 70 orexin receptor-targeting compounds 
patented (Coleman and Renger, 2010). Dysregulation of orexin system is involved in several 
pathological states like narcolepsy, Parkinson’s disease and addiction (Scammell and Saper, 2005). 
Thus orexin research is, and will be, a field, which researchers will find of interest for some time to 
come. 
2.3.1. Structure of orexin peptides 
Both orexin-A and orexin-B are derived from the same prepro-orexin precursor through proteolytic 
processing (Sakurai et al., 1999). Prepro-orexin is a 131 amino acid (aa) long peptide, consisting of 
a secretory signal sequence, 31 aa long orexin-A and 28 aa long orexin-B. Mature orexin-A is post-
translationally modified with an N-terminal pyroglutamic acid (Figure 3) (Sakurai et al., 1998). 
Orexin-A includes four Cys residues, which form two intrachain disulfide bonds. These Cys 
residues are conserved among different species. The amino acid sequences of orexin-A and orexin-
B are rather conserved among mammals but are more diverse in lower vertebrates (Kukkonen, 
2013b). 
2.3.2. Orexin receptors 
Orexin receptors, OX1 and OX2, belong to the GPCR receptor family. Orexin peptides and receptors 
were actually found when a large number of orphan GPCRs were screened for endogenous ligands 
(Sakurai et al., 1998). In humans, OX1 and OX2 receptors have 64% homology in their amino acid 
sequences (Kukkonen, 2013b). Orexin peptides have distinct binding affinities for the orexin 
receptors. Affinities of orexin-A are similar for both the OX1 and OX2 receptors while the binding 
affinity of orexin-B is higher for the OX2 than OX1 receptor (Sakurai et al., 1998). This may also be 
reflected in the potency of the peptides (see, 5.3. Impact of the expression system on orexin 
agonist discrimination).    
2.3.3. Distribution of orexin receptors and peptides 
Orexin peptide and receptor distribution studies are based either on the antibodies, for instance for 
radioimmunoassay and immunohistochemistry methods, or on measuring the expression level of 
mRNA by in situ hybridisation or reverse transcription polymerase chain reaction (RT-PCR). 
Orexin antibodies have been observed to cross-react with other antigens and GPCR antibodies 
(including orexin receptor antibodies) (Kukkonen, 2013b). Thus the results achieved solely by 
methods based on the orexin antibodies, should be questioned, and thus they have been overlooked 
in this review. 
 Orexin peptide and receptor mRNAs are detected in the CNS and several peripheral tissues. In 
rodents, orexin peptides producing neurons are primarily expressed in the lateral hypothalamus and 
also in nearby regions, like posterior hypothalamus (de Lecea et al., 1998; Kukkonen et al., 2002; 
Stoyanova et al., 2010). From these regions, neurons project to other hypothalamic nuclei and 
forebrain, midbrain, and brain stem regions (Kukkonen et al., 2002). Orexin neuron projections are 
also found in the rat spinal cord, where orexins may be involved in the modulation of 
somatosensory information (Date et al., 2000). Of the peripheral tissues, prepro-orexin mRNA is 
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detected, for instance, in rat testis and human adrenal gland, pancreas and stomach (Johren et al., 
2001; Nakabayashi et al., 2003). 
 High expression of OX1 mRNA is detected in the rat hypothalamus, thalamus, and substantia 
nigra (Hervieu et al., 2001). In the peripheral tissues, OX1 mRNA is expressed, for instance, in the 
human adipose tissue and testis and in the rat adrenal gland and pancreas (Kirchgessner and Liu, 
1999; Lopez et al., 1999; Karteris et al., 2004; Digby et al., 2006). In the CNS, sites of OX2 mRNA 
expression partly overlap with the expression sites of OX1, for instance, in the hypothalamus and 
thalamus (Cluderay et al., 2002). However, their expression patterns are mainly distinct, which may 
indicate differential regulation of physiological effects by the orexin receptor subtypes (Tsujino and 
Sakurai, 2013). In the peripheral tissues, expression of OX2 is mostly similar to the expression of 
OX1 but there are some minor exceptions. In some peripheral tissues, like in the kidney and testis, 
only the expression of OX1 mRNA is found, whereas in the lung, only OX2 mRNA is expressed 
(Johren et al., 2001). The expression levels of orexin receptor subtypes may vary according to 
gender. In the adrenal gland, OX2 mRNA expression levels are much higher in male than in female 
rats, and in the hypothalamus OX1 expression levels are higher in female than in male rats (Johren 
et al., 2001). This indicates, for instance, that sex steroids may be involved in the regulation of 
orexin receptor expression levels. 
2.3.4. Orexin receptor signalling 
It is assumed that both orexin receptor subtypes couple to Gq. That assumption is based on the fact 
that activation of the orexin receptors induces an increase in the intracellular calcium concentration 
(Sakurai et al., 1998). This assumption is rather premature, however. It is not easy to determine G-
protein coupling of a GPCR. That is, for instance, because of limited number of molecular tools, 
and also because disturbing the cellular environment in the measurements may ultimately prevent 
the signalling of the G-protein (Kukkonen, 2004;  2013b). Detecting changes in the activity of AC 
or PLC after receptor activation should not be directly concluded to be due to coupling of the 
receptor to certain G-protein, as both AC and PLC are regulated in many ways (Kukkonen, 2013b). 
Despite the complex and still partly uncharacterised signalling of the orexin receptors, some of the 
best known signalling properties of the orexins are summarised here and in the figure 2. 
2.3.4.1. Elevation of the intracellular calcium concentration 
Sakurai et al. originally showed the elevation of intracellular calcium concentration ([Ca
2+
]i) after 
orexin receptor activation in Chinese hamster ovary (CHO) cells (Sakurai et al., 1998). Later orexin 
receptors have been shown to also have the same ability in other cell types, like in neuronal cells 
isolated from hypothalamus, cortex or spinal cord and in recombinant neuro-2a, PC12 and HEK-
293 cell lines (Holmqvist et al., 2002; Kukkonen et al., 2002; Magga et al., 2006; Putula et al., 
2011b). Elevation of [Ca
2+
]i occurs in two different ways. Stimulation of the orexin receptor leads to 
activation of PLC, probably through receptor coupling to Gq, and PLC catalyses the formation of 
IP3 (Uramura et al., 2001). IP3 elevates intracellular calcium by releasing intracellular calcium from 
the ER and indirectly through activating store-operated calcium channels (SOCs) and thus causing 
calcium influx. On the other hand, increased [Ca
2+
]i is achieved through opening of receptor-
operated calcium channels (ROCs) that leads to influx of calcium through the channels. ROC 
activation does not require IP3 but, instead, phospholipase A2 (PLA2) activity seems to be necessary 
for this (see, 2.3.4.3. Regulation of lipid signalling). Activation of ROCs and SOCs is dependent 
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on the concentration of orexin-A, at least in recombinant cell models. At low orexin-A 
concentration, ROCs are primarily responsible for calcium elevation, and Ca
2+ 
influx through ROCs 
somehow enhances PLC activation, which triggers Ca
2+
 release from the ER and activation of SOCs 
(Lund et al., 2000; Kukkonen and Åkerman, 2001; Johansson et al., 2007; Turunen et al., 2010; 
Turunen et al., 2012). At high orexin-A concentration, PLC activation is independent of ROCs 
(Lund et al., 2000; Kukkonen and Åkerman, 2001). 
2.3.4.2. Regulation of the activity of adenylyl cyclase 
Three different pathways for orexin receptors to regulate the activity of AC have been shown. 
Firstly, OX1 can couple to Gs and thus stimulate AC and cAMP production (Holmqvist et al., 2005). 
Another way to stimulate AC is via coupling to Gq and activation of PKC, which is known to be a 
stimulator of some AC isoforms (Kawabe et al., 1994). In addition to stimulatory effects, inhibitory 
effects in AC regulation have also been seen (Holmqvist et al., 2005). That is probably mediated via 
OX1 coupling to Gi-protein as the inhibition can be prevented with pertussis toxin. In some reports, 
no changes in cAMP levels after orexin receptor activation are detected at all (Magga et al., 2006). 
Altogether, the variation in results may be due to differences in cell types or experimental setups 
used. In addition, AC is regulated in multiple ways, not only by Gs- and Gi-proteins. It is likely, 
however, that both OX1 and OX2 receptors couple to Gαi, Gαs, and Gαq families of G-proteins, but 
that is only shown indirectly (Kukkonen, 2013a;  b; Kukkonen and Leonard, 2013). 
 Stimulation of the activity of adenylyl cyclase is involved in glucocorticoid release in human 
adrenocortical cells (Mazzocchi et al., 2001). That release is mediated by orexin-A binding to OX1 
receptor, which activates adenylyl cyclase-dependent cascade. This may be one way orexins are 
involved in the maintenance of our energy homeostasis.    
2.3.4.3. Regulation of lipid signalling 
Several phospholipase isoforms, including PLA, PLC, and PLD, are activated after stimulation of 
orexin receptor in recombinant cell lines (Kukkonen, 2013b). Upon OX1 receptor activation, release 
of arachidonic acid (AA) is detected in recombinant CHO cells (Turunen et al., 2010). AA is the 
major end product of PLA2 activity and cytosolic PLA2 (cPLA2) in particular is involved in orexin 
receptor signalling (Turunen et al., 2012). There is a strong connection between the release of AA 
and elevation of [Ca
2+
]i, especially through ROCs. Reduction of the extracellular Ca
2+
 abolishes the 
orexin-mediated release of AA (Turunen et al., 2010). On the other hand, blocking of the PLA2 
activity, and thus AA release, with methyl arachidonyl fluorophosphonate (MAFP) or 
pyrrophenone, causes a notable inhibition in the orexin receptor-operated Ca
2+ 
influx (Turunen et 
al., 2012). Thus it is speculated that AA release and Ca
2+
 influx create a positive feedback loop in 
the orexin receptor signalling (Turunen et al., 2010). 
 It is generally assumed that orexin receptors couple to Gq-protein and thus activate PLCβ. It 
seems that at least two different isoforms of PLC are activated in orexin signalling cascades in the 
CHO cells (Johansson et al., 2008), but the identity of these is unknown. Similar to the activation of 
PLA, PLC activation is also regulated by Ca
2+
 influx, more prominently through ROCs. ROCs thus 
seem to have a very important role in orexin receptor signalling (Johansson et al., 2007). 
 Stimulation of OX1 receptors activates PLD, most likely PLD1 isoform (Jäntti et al., 2011). 
PLD hydrolyses phosphatidylcholine to choline and phosphatidic acid (PA), which is an 
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intracellular messenger. PA indirectly actives the production of PIP2, which is, on the other hand, 
needed for the PLD activity. PA can be converted to DAG, and thus PLD activation causes increase 
both in PA and DAG concentrations (Jenkins and Frohman, 2005). Activation of PLD1 after orexin 
receptor stimulation occurs via PKC. The exact targets of PLD in orexin receptor signalling are still 
unknown. 
 Even though most of the knowledge regarding orexin-mediated regulation of lipid signalling 
originates from studies with recombinant cell lines, there are, however, some studies that have been 
conducted in native neuronal cells. Orexin-induced PKC activation may mediate responses like 
Ca
2+
 signalling and cell depolarisation, in, at least, rat dopamine neurons or neurons in the 
prefrontal cortex or nucleus tractus solitarius (Uramura et al., 2001; Yang et al., 2003; Song et al., 
2005). 
 Endocannabinoids are AA-containing lipid-derived messenger molecules (Pertwee, 2006). 
The best known endocannabinoids are 2-arachidonylglycerol (2-AG) and N-
arachidonylethanolamine (anandamide). Orexin-A-induced activation of OX1 receptor triggers the 
release of 2-AG from the PLC-produced DAG in a reaction catalysed by DAG lipase (DGL) 
(Turunen et al., 2012; Kukkonen, 2013b). Previous studies have proposed formation of heteromers 
between orexin receptors and endocannabinoid receptors (Ellis et al., 2006; Ward et al., 2011), 
however, current findings suggest that heteromerisation is not necessary. In a cell-cell 
communication assay, 2-AG released upon OX1 receptor stimulation activates endocannabinoid 
signalling through binding to endocannabinoid receptor CB1 in the same or neighbouring cells 
(Turunen et al., 2012; Jäntti et al., 2013). The role of orexinergic and endocannabinoid system 
connection in physiological functions is still partly unclear although some interesting findings of 
their co-operation have been made. Both orexins and endocannabinoids have a role as regulators of 
appetite, and orexin-A-induced appetite can be blocked with the CB1 antagonist rimonabant (Crespo 
et al., 2008). Another overlapping function between orexinergic and endocannabinoid systems is 
seen in the regulation of analgesia (Kukkonen, 2013b). It is speculated that orexin signalling-
induced 2-AG production in the periaqueductal gray matter, the site crucial for descending pain 
inhibition, results in CB1 receptor activation and, finally, inhibition of GABAergic signalling and 
antinociception (Ho et al., 2011).    
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Figure 2. Schematic figure of orexin receptors signalling based on the signalling pathways 
described in the text. Arrows with solid line indicate activation of enzymes and arrows with dashed 
line indicate products of enzymatic reactions. Blunt end arrows indicate inhibition. The mechanism 
for the transport of 2-AG over the membrane is unclear, and thus it is indicated here with a wave 
line. 2-AG, 2-arachidonylglycerol; CB1, cannabinoid receptor type 1; cPLA2, cytosolic 
phospholipase A2; DGL, diacylglycerol lipase; ER, endoplasmic reticulum; IP3R, inositol 
triphosphate receptor; OX1, OX1 orexin receptor; OX2, OX2 orexin receptor; OX-A, orexin-A; OX-
B, orexin-B; PA, phosphatidic acid; PIP2, phosphatidylinositol-4,5-biphosphate; PLD, 
phospholipase D; ROC, receptor-operated calcium channel; SOC, store-operated calcium channel.  
2.3.5. Physiological functions of orexins 
As orexin peptide and receptor expression is detected in multiple peripheral tissues, orexins can be 
expected to have several different physiological functions. Some of the physiological functions for 
orexins were identified already at the time orexins were found and some later using genetically 
modified animal models (Sakurai et al., 1998; Kukkonen, 2013b). 
2.3.5.1. Regulation of energy homeostasis 
Sakurai and his co-workers were the first researchers to detect that central administration of orexin-
A causes an increase in appetite in rats (Sakurai et al., 1998). That effect, as well as fasting-
32 
 
stimulated appetite, can be blocked with the OX1-specific antagonist SB-334867 (Haynes et al., 
2000). Later, a link between orexin neuron activity and blood glucose level has been shown 
(Burdakov et al., 2005). When the blood glucose level is low, production of orexins is up-regulated, 
and during the high blood glucose level, orexin production decreases (Tsuneki et al., 2012). Thus 
orexins can stimulate appetite when necessary and that way participate in short-term regulation of 
energy homeostasis (Kukkonen et al., 2002). In addition to sensing glucose, orexin neurons also can 
sense dietary amino acids, and especially nonessential amino acids can potently activate orexinergic 
neurons (Karnani et al., 2011). In addition to stimulation of orexin neurons by low glucose level, 
orexin neurons can be excited by ghrelin, which is an appetite-stimulator, and inhibited by leptin, 
which can regulate energy homeostasis in multiple ways (Scammell and Winrow, 2011). Orexin 
neurons also directly interact with neuropeptide Y (NPY) and proopiomelanocortin (POMC) 
neurons, which are involved in stimulation and inhibition of feeding, respectively. The ability of 
orexin neurons to activate NPY neurons and inhibit POMC neurons partly causes the feeding-
stimulating effect of orexin neurons (Muroya et al., 2004). However, all the responses seen with 
respect to regulation of energy homeostasis are from studies where orexin is administrated to the 
animals. Thus we cannot be sure, whether the same physiological responses are seen after “native” 
orexin release. 
2.3.5.2. Regulation of sleep-wakefulness cycle 
A high activity of orexin neurons is detected in areas involved in the regulation of arousal states. 
That indicates a central role of orexins in the control of sleep-wakefulness cycle, and indeed 
stimulation of orexin neurons has been shown to increase arousal (Hagan et al., 1999). Orexins have 
been shown to excite several monoaminergic systems, including noradrenergic, dopaminergic, 
histaminergic and serotoninergic neurons, and these neurons are speculated to mediate the arousal-
promoting effects of orexins (Hagan et al., 1999; Nakamura et al., 2000; Liu et al., 2002; Yamanaka 
et al., 2002). The histaminergic neurons seem to be the most important target for the orexinergic 
system as it is reported that stimulation of histaminergic neurons via OX2, is the main approach by 
which the orexinergic system promotes arousal (Yamanaka et al., 2002). Increased rapid eye 
movement (REM) sleep is seen in prepro-orexin knockout mice, which also show other symptoms 
of narcolepsy (Chemelli et al., 1999; Kukkonen, 2013b). As orexin has been shown to be a central 
regulator of arousal states, orexin receptor-targeting drugs could play an important role in the 
treatment of sleep disorders like narcolepsy and insomnia. 
2.3.5.3. Regulation of thermogenesis 
Brown adipose tissue (BAT) is the main heat producer in rodents and it has significant role in 
maintaining body temperature (Morrison et al., 2012; Kukkonen, 2013b). Thermogenesis in BAT is 
controlled by the sympathetic nervous system. In addition to thermoregulation, BAT is involved in 
the regulation of body weight (Morrison et al., 2012). Interestingly, orexin-deficient mice are obese 
although they eat less than control individuals, and that has been suggested to be caused by 
impaired thermogenesis in BAT (Hara et al., 2001; Sellayah et al., 2011). The impaired 
thermogenesis is speculated to be caused by the inability of BAT cells to differentiate in the absence 
of orexins (Sellayah et al., 2011). The defective brown adipocytes cannot, for instance, accumulate 
triglycerides. The impaired thermogenesis is not necessarily the only explanation for the obesity of 
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orexin-deficient mice, however, as the obesity is found to also be dependent on the genetic 
background and environmental factors (Hara et al., 2005).  
2.3.5.4. Regulation of reward system 
Narcolepsy, a neurological disorder likely caused in humans by reduction in the number of orexin-
producing neurons, is typically treated with psychostimulants like amphetamine or methylphenidate 
(Mitler and Hayduk, 2002). These drugs typically cause strong addiction but, interestingly, in 
narcoleptic patients no addiction is usually detected (Tsujino and Sakurai, 2013). Orexin neurons 
receive projections from the ventral tegmental area and nucleus accumbens, both of which are 
important areas in the reward system and thus also in addiction (Harris et al., 2005). The 
orexinergic system has been shown to have an important role especially in food and drug rewards 
(Mahler et al., 2012). 
 Orexin receptor antagonists, like the OX1-specific SB-334867 and the OX2-specific JNJ-
10397049, have been shown to cause reduction of ethanol self-administration in alcohol-preferring 
rats (Lawrence et al., 2006; Shoblock et al., 2011). Orexins are also involved in the alcohol relapse 
process, and alcohol seeking activates orexin neurons (Dayas et al., 2008). Blocking OX1 with SB-
334867 has been shown to reduce alcohol relapse (Dhaher et al., 2010). Taken together, orexin 
seems to have a role in the development of addiction. Prevention of the relapse to drug seeking thus 
offers a new target for orexinergic drugs (Perez-Leighton et al., 2013).  
2.3.5.5. Other functions 
Intracerebroventricular injection of orexin-A and -B induces stress-like symptoms, like increased 
heart rate and blood pressure (Shirasaka et al., 1999; Smith et al., 2002). Orexins can also increase 
typical stress behaviour in rats, and the behaviour can be blocked with SB-334867 (Duxon et al., 
2001). This phenomenon may be based on the ability of orexins to regulate the release of several 
hormones involved in stress response (Kukkonen et al., 2002; Scammell and Winrow, 2011; 
Kukkonen, 2013b). These hormones include, for instance, noradrenalin, glucocorticoids, and 
vasopressin. 
 Orexin-A has also shown to be an effective anti-noniceptive and anti-hyperalgesic regulator at 
least in rodents. Intracerebroventricular or intravenous injection of orexin-A increases analgesia in 
the hotplate test and the effect can be blocked with the OX1-specific antagonist SB-334867 
(Bingham et al., 2001). Antinociceptive effect of orexin may occur through, or together with, 
adenosine or endocannabinoid signalling (Kukkonen, 2013b). 
2.3.6. Pathological states associated with malfunction of orexinergic 
system 
As the orexinergic system regulates many important physiological functions, it is easy to understand 
that malfunction of orexin-producing or orexin-responsive neurons may cause severe conditions. 
Some of these pathological conditions are more obvious, like narcolepsy, but some are less well 
studied, like the possible involvement of the orexinergic system in neurodegenerative disorders. 
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2.3.6.1. Narcolepsy 
Narcolepsy is a sleep disorder characterised by excessive daytime sleepiness and rapid transition 
from wakefulness into REM sleep (Chemelli et al., 1999; Mitler and Hayduk, 2002). Narcoleptic 
patients may also express cataplexy attacks, meaning that they can suddenly loose their muscle 
tone, usually after some emotional situation like laughing. Some patients also suffer from 
parasomnia. The reported prevalence of narcolepsy varies between 0.02 and 0.18% in different 
countries (Mignot, 1998). In humans, narcolepsy is mostly a sporadic disease although in dogs 
familial forms have also been found (Lin et al., 1999; Kukkonen, 2013b). 
 Only a year after the discovery of orexins, there were two studies published that described the 
involvement of the orexinergic system in narcolepsy in animal models. Prepro-orexin knockout 
mice showed narcolepsy-like symptoms, like disturbances in REM sleep regulation (Chemelli et al., 
1999). That was seen in the night time, which is normally the active time of mice. These mice also 
showed reduced activity and cataplectic attacks during the night time, when compared to control 
mice. Another study described that mutations in the OX2 gene are associated with narcolepsy in 
dogs. Narcoleptic Labrador retrievers and Doberman pinchers were shown to have deletion of one 
exon (exon 4 in Doberman pincher and exon 6 in Labrador retriever) in their OX2 gene (Lin et al., 
1999). Deletions lead to a reading frame shift in the mRNA for the OX2 gene and formation of a 
premature stop codon. 
 In human narcoleptics, a reduced level of orexin-A in cerebrospinal fluid can be detected 
(Nishino et al., 2000; Thannickal et al., 2000). That reduction is caused by death of orexin-
producing neurons; up to 90% of orexin neurons may be lost (Thannickal et al., 2000). The reason 
for the orexin neuron death is still unclear, but certain human leukocyte antigen class II haplotypes 
are strongly associated with narcolepsy, indicating a possible autoimmune origin of narcolepsy 
(Chemelli et al., 1999; Kukkonen, 2013b).   
2.3.6.2. Neurodegenerative disorders 
The human prepro-orexin gene is located on chromosome 17q21, which is the site typically 
associated with neurodegenerative disorders. Especially dementia symptoms of neurodegenerative 
diseases, like Alzheimer’s or Parkinson’s disease, are linked to that chromosome (Wijker et al., 
1996; Foster et al., 1997; Sakurai et al., 1998). Symptoms of Alzheimer’s disease include cognitive 
disturbances and also narcolepsy-related symptoms like excessive daytime sleepiness and disturbed 
REM sleep. As in the human narcoleptics, and Alzheimer’s disease patients, the numbers of orexin 
neurons and levels of peptides are significantly decreased (Fronczek et al., 2012). Orexin neurons 
are not the only neuron type degenerating in Alzheimer’s disease, however, as other neurons that 
are also involved in arousal state regulation are damaged. In addition to Alzheimer’s disease, orexin 
neuron loss has been seen in patients with Huntington’s and Parkinson’s diseases (Fronczek et al., 
2007; Thannickal et al., 2007; Aziz et al., 2008). 
2.3.6.3. Obesity 
Obese humans are also reported to have a lowered level of orexin-A in plasma, even though that has 
only been shown with the purported unreliable orexin-A-specific antibodies (Adam et al., 2002). 
However, that may indicate that orexin has a role in energy expenditure. Indeed, mice with no 
orexin neurons are less spontaneously active than control mice (Chemelli et al., 1999). Orexin-
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induced thermogenesis in BAT also increases energy expenditure (Morrison et al., 2012). Increased 
energy expenditure requires simultaneous activation of orexin receptors in different brain regions, 
but it remains unknown how this interaction between different regions happens. Interestingly, 
orexin peptide over-expression protects from the obesity caused by a high-fat diet (Funato et al., 
2009). This effect is mediated in particular by OX2 receptor signalling. 
 Shorter sleep time and sleep stability are linked with development of obesity in humans 
(Spiegel et al., 2009). Orexin receptor signalling through multiple brain regions affects our 
behaviour, like feeding, sleeping and activity. Together with sympathetic nervous activity, which 
also is regulated by orexins, these regulate our energy expenditure. Thus orexins seem to form a 
link between arousal and energy homeostasis (Van Cauter and Knutson, 2008). 
2.3.7. Orexin receptor pharmacology 
As described above, orexin-A has higher binding affinity for OX1 receptor than orexin-B (Sakurai 
et al., 1998). One should keep in mind, however, that affinity of orexin peptides also depends on the 
expression levels of G-proteins and orexin receptors (Kukkonen et al., 2002). If the level of 
expressed G-proteins and receptors is low, the ”productive” ligand-receptor complexes are more 
scarce. The detected low signal may thus incorrectly be concluded to be caused by low affinity or 
efficacy.   
 Molecular determinants for orexin peptide binding and functionality in the orexin receptors 
have been studied with chimaeric and point-mutated receptors and truncated and alanine-scanned 
peptides (Darker et al., 2001; Ammoun et al., 2003; Putula et al., 2011b; Tran et al., 2011; Putula 
and Kukkonen, 2012). The transmembrane helixes two, three, and four seem to be the most crucial 
in determining the orexin receptor subtype selectivity for orexin agonists (Malherbe et al., 2010; 
Putula et al., 2011b; Tran et al., 2011). Apparently, the same areas are important for antagonist 
selectivity too (Malherbe et al., 2010; Tran et al., 2011; Heifetz et al., 2012; Putula and Kukkonen, 
2012). These studies are more closely discussed in the results and discussion chapter. In orexin-A, 
the C-terminus is the most important part to contribute to the OX1 receptor activation and thus 
binding as well (Darker et al., 2001; Ammoun et al., 2003). That also seems to be the case for the 
OX2 receptor, but OX2 seems to require fewer determinants for orexin-A binding as it is more 
resistant towards peptide truncation and other mutagenesis (Ammoun et al., 2003). The C-terminal 
part of the orexin-B is also the most important for the orexin-B-caused receptor activation (Lang et 
al., 2004).   
2.3.7.1. Orexin receptor agonists 
Possibilities for studies of orexin agonisms are limited because of the low number of available 
agonists. There are no published studies of behavioural responses to exogenously administered 
orexin peptides in humans. It is known, however, that intranasally administrated orexin-A can 
increase cognition in nonhuman primates exposed to sleep deprivation (Deadwyler et al., 2007). 
 In narcoleptic mouse models, orexin-A administration has been shown to increase 
wakefulness and decrease cataplectic attacks (Mieda et al., 2004). Thus it is expected that orexin 
receptor agonists could also have medical use in the treatment of narcolepsy in humans. 
Neurodegenerative disorders with symptoms like sleep disturbances might be treatable with orexin 
agonists (see, 2.3.6.2. Neurodegenerative disorders). Yet another potential use of orexin agonists 
could be in the treatment of cancer (Voisin et al., 2011). That is because orexin receptor activation 
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mediates apoptosis in colon cancer and neuroblastoma cells (Rouet-Benzineb et al., 2004; Ammoun 
et al., 2006b; Voisin et al., 2006). Also obesity, both in humans and in animals, might be treatable 
with an orexin agonist, as it has been shown that orexin peptide overexpression protects rodents 
from diet-induced obesity (Funato et al., 2009). 
 However, all the currently available agonists are peptides, which do not have good properties 
to be used as drugs. For instance, bioavailability by orally administrated peptide drug is low 
because peptides are quickly inactivated by gastrointestinal enzymes and also large peptides 
penetrate intestinal membranes poorly (Morishita and Peppas, 2006). Intravenously injected 
peptides are quickly inactivated and often have poor CNS penetrance. There is only one non-
peptide orexin agonist reported in a patent application (Yanagisawa, 2010). 
 There are some synthetic, modified orexin peptides created to study the interaction between 
receptor and the ligand (Gotter et al., 2012). For instance, [Ala
11
, D-Leu
15
]-orexin-B is a 
commercially available orexin agonist, suggested to show OX2-selectivity (Asahi et al., 2003). Only 
a 10-fold difference in the relative potency between the receptors was seen as compared to orexin-A 
(Putula et al., 2011a). In addition, there is a small molecule allosteric OX2 potentiator, which does 
not bind to the ligand binding pocket of the orexin receptor but may potentiate the response of the 
receptor to its cognate ligand (Lee et al., 2010). 
2.3.7.2. OX1 receptor-specific antagonists 
Most of the orexin receptor antagonists are developed to treat insomnia (Coleman and Renger, 
2010; Scammell and Winrow, 2011). Currently, the clinically used hypnotics are mainly based on 
enhancing the signalling of γ-aminobutyric acid (GABA) (Liu and Wang, 2012). These are involved 
in many brain functions, however, and interfering with their signalling causes unwanted side effects 
like confusion, tolerance, drug abuse and morning sedation (Scammell and Winrow, 2011). Using 
orexin receptor antagonists as hypnotics might involve fewer side effects (Scammell and Winrow, 
2011). In addition to insomnia, orexin antagonists might find use, at least, in the treatment of eating 
disorders or addiction (Coleman and Renger, 2010; Scammell and Winrow, 2011; Gotter et al., 
2012).  
The pharmaceutical company GlaxoSmithKline (GSK) published the first OX1 receptor-
selective antagonist, 1-(2-methyylbenzoxanzol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride 
(SB-334867), in 2001 (Smart et al., 2001). The binding affinity of SB-334867 favours OX1 with a 
50-fold difference compared to OX2, and thus high doses of this antagonist may result in the 
blocking of both receptor subtypes (Smart et al., 2001; Scammell and Winrow, 2011). Sometimes 
SB-334867 is also detected to work as a weak agonist (Kukkonen, 2013b). Some other concerns 
include that SB-334867 has been reported to interact with at least seven other targets in addition to 
OX1 receptor (Gotter et al., 2012). Recently SB-334867 was reported to be readily hydrolysed in 
acidic and basic conditions (McElhinny et al., 2012). However, as SB-334867 has favourable 
pharmacokinetic properties and easy availability commercially, it is a popular tool when studying 
orexin receptor signalling and animal behaviour in vivo (Gotter et al., 2012). It has been reported, 
for instance, to reduce alcohol consumption and food intake in rodents (Haynes et al., 2002; Jupp et 
al., 2011). In addition to SB-334867, GSK has also developed related OX1-specific antagonists, like 
SB-408124, SB-410220, and SB-674042 (Scammell and Winrow, 2011).  
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2.3.7.3. OX2 receptor-specific antagonists 
Hoffmann-La Roche has published a highly OX2-selective antagonist, N-ethyl-2-[(6-methoxy-
pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA), which shows 
up to 900-fold selectivity when compared to OX1. It has reported to reduce physical activity in 
rodents, but no other physiological effects are published so far (Malherbe et al., 2009a). Johnson & 
Johnson has developed an OX2-specific antagonist, 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-
4-phenyl-1,3-dioxan-5-yl]urea (JNJ-10397049), which displays about 600-fold selectivity for OX2, 
and was shown to increase sleep in rats (McAtee et al., 2004; Dugovic et al., 2009). JNJ-10397049 
has also been shown to reduce extracellular histamine concentration in the lateral hypothalamus, 
which may be the way the compound can promote sleep (Dugovic et al., 2009). 
2.3.7.4. Dual orexin receptor antagonists 
OX1 knockout mice do not show signs of disturbed sleep regulation, but deletion of OX2 causes 
increased sleepiness (Scammell and Winrow, 2011). When both receptor subtypes are deleted, mice 
display symptoms very similar to narcolepsy (Willie et al., 2003). Thus, it can be speculated that 
OX2 receptor-specific antagonists could be fairly effective sleep promoters, but an antagonist, 
which blocks both receptor subtypes, could be the best way to treat insomnia (Scammell and 
Winrow, 2011). Actually, development of dual orexin receptor antagonists (DORAs) seems to be 
the highest priority in pharmaceutical companies, when it comes to finding new drugs targeting 
orexin receptors. 
 GSK has developed a DORA called SB-649868. It was shown to be an effective and well- 
tolerated sleep promoter in men with primary insomnia (Bettica et al., 2012). The drug entered 
phase II studies but its development was later halted because of toxicity (Gotter et al., 2012). 
 Actelion originally developed another promising DORA called (2R)-2-[(1S)-6,7-dimethoxy-1-
(2-[4-(trifluoromethyl)phenyl]ethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-
phenylethanamide (almorexant). Later, GSK started to collaborate with Actelion in this project 
(Coleman and Renger, 2010). Almorexant promotes sleep when administrated orally to healthy 
animals and humans during the active period of the circadian cycle (Brisbare-Roch et al., 2007; 
Malherbe et al., 2009b). In human trials, almorexant was shown to be a very effective sleep inducer 
in people with primary insomnia (Hoever et al., 2012). Development of almorexant continued until 
phase III, but was recently discontinued due to its tolerability profile (Gotter et al., 2012). 
 Merck has also produced some promising DORA compounds: DORA-1 and DORA-5 were 
reported to increase sleep in rodents (Gotter et al., 2012). The most promising DORA by Merck, 
and also the most promising orexin antagonist so far, is [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)- 
7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (suvorexant) 
(also known as MK-4305). Suvorexant is orally bioavailable and also has good brain penetration 
(Cox et al., 2010). In rodents, dogs and monkeys, it has been shown to reduce physically active time 
and increase REM sleep (Cox et al., 2010; Herring et al., 2012). Suvorexant is well-tolerated in 
humans and it has been shown to be an effective sleep inducer among people with primary insomnia 
(Herring et al., 2012; Sun et al., 2013). The phase III studies of suvorexant are now completed, and 
new drug application for suvorexant was recently under the review by U.S. Food and Drug 
Administration (FDA). However, FDA did not accept the application as such but wants to decrease 
the dosing of suvorexant (http://www.mercknewsroom.com/press-release/research-and-
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development-news/merck-receives-complete-response-letter-suvorexant-merck). In any case, 
suvorexant has the potential to become the first orexin receptor targeting drug on the market.     
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Figure 3. A) Alignment of orexin-A, orexin-B and [Ala
11
, D-Leu
15
]-orexin-B amino acid 
sequences. Disulfide bonds of orexin-A are marked. The peptides are C-terminally amidated and the 
first N-terminal glutamine of orexin-A is cyclised to pyroglutamyl. The fifteenth amino acid of 
[Ala
11
, D-Leu
15
]-orexin-B is substituted from L-leucine to D-leucine. B) Structures of the orexin 
receptor antagonists mentioned in the text. 
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3. Aims of the study 
At the commencement of this doctoral thesis, there were no studies published on the molecular 
determinants of orexin receptors needed for ligand binding or selectivity. Thus, orexin receptor 
chimaeras were created to map the selectivity-conferring areas for orexin agonists and antagonist. In 
the later part of these studies the attempt was to optimise an orexin binding assay and use it, along 
with other methods, to study the impact of Ca
2+
 concentration to orexin ligand-receptor interaction 
and orexin signal transduction. The aims of the studies overall were: 
1) To map the molecular determinants of the orexin receptor needed for the selectivity of 
orexin agonists orexin-A, orexin-B, and [Ala
11
, D-Leu
15
]-orexin-B (Papers I and II). 
2) To map the molecular determinants of the orexin receptors needed for the OX1-selectivity of 
the antagonist SB-334867 (Paper III). 
3) To study the impact of extracellular Ca2+ in the binding of orexin-A to OX1 receptor and in 
the enzymatic activity of PLC and AC (Paper IV). 
4. Material and methods 
4.1. Cell culture (Papers I-IV) 
CHO cells expressing human OX1 (Papers I and IV) or human OX2 receptor (Paper I) were cultured 
in Ham’s F-12 medium supplemented with 100 U/ml penicillin, 80 U/ml streptomycin, 10% (v/v) 
fetal calf serum (FCS), 2.5 mM L-glutamine, and 10 mM Hepes (Hepes only in Paper IV). G418 
(400 μg/ml) was used as a selection marker. HEK-293 human embryonic kidney cell line was used 
in Papers I, II, and III. HEK-293 cells were cultured in high glucose Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 100 U/ml penicillin, 80 U/ml streptomycin, 10% FCS, 2 mM 
UltraGlutamine, and 15 mM Hepes. Both CHO and HEK-293 cells were cultured at 37 °C in 5% 
CO2 in an air-ventilated humidified incubator. 
 For the Ca
2+
 assay (Papers I and II), CHO and HEK-293 cells were cultured on 96-well 
polystyrene plates, which were pretreated for coating with polyethyleneimine (PEI; 25 μg/ml, 1 h, 
37 °C) for HEK-293 cells. For the binding and SPA assays (Paper IV) CHO-OX1 cells were 
cultured on 48-well plates or 96-well SPA plates similarly pretreated with PEI. For the IP and 
cAMP release assays CHO-OX1 cells were culture on PEI-treated 48-well plates (Paper IV) and 
HEK-293 cells were cultured on 56-cm
2
 dishes (Paper III). 
4.2. Experimental media (Papers I–III) 
The standard experimental medium in all studies is called Hepes-buffered medium (HBM; Papers 
IIII) or Na+-based medium (NaBM; Paper IV). Independent of the name, it has the same 
composition of 137 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1.2 mM MgCl2, 0.44 mM KH2PO4, 4.2 
mM NaHCO3, 10 mM glucose, 2.5 mM probenecid, and 20 mM Hepes; pH adjusted to 7.4 with 
NaOH. For final experiments, HBM/NaBM was usually supplemented with 1 mM CaCl2 (Papers 
IIV) and sometimes with Ca2+ and/or EGTA to obtain lower Ca2+ concentrations (Paper IV). For 
the PLC assay, it was supplemented with 10 mM LiCl2. In K
+
-based medium (KBM), all Na
+
 salts 
in NaBM were replaced with corresponding K
+
 salts; this medium was mixed with regular HBM in 
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a ratio 0.86:0.14, respectively, to yield a medium called High-K
+
-NaBM with a K
+
-concentration of 
127 mM and 1 mM CaCl2 (Paper IV). In TEA-NaBM, 70 mM of NaCl of HBM was replaced with 
tetraethylammonium chloride (TEA) and 1 mM CaCl2 was added.  
4.3. Construction of the orexin receptor chimaeras (Papers I–III) 
In the first round of mutagenesis (creation of chimaeras Ch1–6, see figure 4), polymerase chain 
reaction (PCR) fragments of OX1 and OX2 receptors were created. Next, these fragments were 
combined to create two-part receptor chimaeras with the N-terminus of the receptor protein from 
the OX1 and C-terminus of the receptor protein from the OX2 receptor, and vice versa. Chimaeric 
receptors did not include amino acid changes except the stop codon was mutated to GGA to allow 
the fusion of the receptor with C-terminal GFP. In the second round of mutagenesis, four additional, 
three-part chimaeras (Ch7–10, Figure 4) were created utilising the native restriction sites in the 
chimaeras Ch1–6. OX1-GFP and OX2-GFP receptors were also reconstructed from the chimaeras 
Ch1–6. For additional information on the construction including the second round of chimaeras 
(Ch710), see Papers II and III (Putula et al., 2011b; Putula and Kukkonen, 2012). 
 
 
 
 
Figure 4. Orexin receptor chimaeras constructed from OX1 and OX2 receptors. Reprinted from 
FEBS Letters, 585(9), Putula J, Turunen PM, Johansson L, Näsman J, Ra R, Korhonen L and 
Kukkonen JP, Orexin/hypocretin receptor chimaeras reveal structural features important for orexin 
peptide distinction, 1368-1374,  2011, with permission from Elsevier (adapted from Putula et al., 
2011b). 
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4.4. Transfections (Papers I–III) 
Fugene HD was used to transiently transfect HEK-293 cells with chimaeric orexin receptors. The 
cells were grown to 40–50% confluence on the 96-well plates (Papers I and II) or 56-cm2 dishes 
(Paper III) and transfected with 0.1 μg DNA and 0.25 μl Fugene HD per well or 10 μg DNA and 25 
μl Fugene HD per dish in Opti-MEM. The cells were transfected 48 h prior to the experiments. 
Transfection efficiency was checked with a fluorescence microscope before the experiments.  
4.5. Ca2+ assay (Papers I and II) 
FLIPR Calcium 4 Assay Kit was used for the calcium measurements in the CHO cells. FLIPR 
medium was prepared by dissolving FLIPR Calcium 4 Assay Kit in Hank’s balanced salt solution 
supplemented with 20 mM Hepes and 5 mM probenecid. 50 μl of this solution was added to the 
CHO cells present in a 96-well plate in 50 μl of cell culture medium. The cells were incubated for 
one hour at 37 °C. For HEK-293 cells, fluo-4 acetoxymethyl ester was used. After 48 h of 
transfection, the cell culture medium was removed and 2 μM fluo-4 in HBM, supplemented with 1 
mM CaCl2, was added to the cells. The cells were incubated for one hour at 37 °C. After the 
incubation, the cells were washed twice with the same HBM. Both CHO and HEK-293 cells were 
measured with the FlexStation automated fluorescence plate reader at 37 °C utilising the 
wavelengths 485 nm (excitation) and 525 nm (emission). Each well was measured for 120 seconds 
and the ligand was added at 30 seconds. The data was analysed and visualised in Microsoft Excel. 
4.6. IP release assay (Papers III and IV) 
In Paper III, HEK-293 cells were transiently transfected with chimaeric orexin receptors, and then 
loaded with 5 μCi/ml of [3H]myo-inositol after 24 hours. For the chimaeras with low expression, 10 
μCi/ml was used for the loading. After 24 h loading, cells were washed with phosphate-buffered 
saline (PBS), detached with PBS containing 0.2 g/l EDTA, spun down and resuspended in HBM, 
which contained 10 mM LiCl. After a 10 min incubation with the LiCl, the cells were dispensed to a 
96-well plate, which already contained orexin-A (0–1000 nM) and SB-334867 (0–10 000 nM). The 
plate was stimulated for 30 minutes at 37 °C. Reactions were stopped by centrifugation (700 g, 1 
min, 4 °C) and rapid removal of the medium. 100 μl of cold 0.4 M perchloride acid was added to 
each well and the plate was frozen down.  
In Paper IV, intact CHO cells stabily expressing OX1 receptor were used. The cells, cultured 
on PEI-coated 48-well plates, were loaded with 3 μCi/ml of [3H]myo-inositol. After a 24-h loading, 
the medium was removed and cells were washed with PBS. Next, 100 μl of one of the following 
media, all containing 10 mM LiCl and 0.1% BSA, to make the assay comparable with the binding 
assay, was added to the cells: HBM/NaBM containing variable concentrations of CaCl2 (100 nM‒1 
mM), HBM/NaBM + 1 mM CaCl2 containing 10 μM SKF-96365 (SOC inhibitor), TEA-NaBM 
(ROC inhibitor, 70 mM final TEA-concentration ) or high-K
+
-NaBM (the final K
+
-concentration 
was 127 mM). High K
+
 concentration depolarises the cells and thus reduces the driving force for 
Ca
2+
 influx. Addition of the LiCl-containing buffer was followed by 10-min incubation at 37 °C and 
then addition of orexin-A in 25 μl volume. The plate was incubated for 10-min at 37 °C. The 
reaction was stopped by rapid removal of the medium. 100 μl of cold 0.4 M perchloride acid was 
added to each well and the plate was frozen down. 
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After thawing the samples (both Papers III and IV), 50 μl of 0.36 M potassium hydroxide / 
0.3 M potassium bicarbonate mixture was added to neutralise the samples. The plates were 
centrifuged for 10 min (400 g, 4 °C), and samples were loaded to BioRad AG 1-X8-anion-exchange 
chromatography columns. Columns were washed with 8 ml of water and 8 ml of mixture of 5 mM 
Na2-tetraborate and 60 mM NH4-formate.  The total inositol phosphate fraction was eluted with 4 ml 
of mixture of 0.1M formic acid and 1M NH4-formate. 8 ml of HiSafe 3 scintillation cocktail was 
added to the samples for counting with Wallac 1414 liquid scintillation counter.     
4.7. Binding assay (Paper IV) 
Optimisation of the binding assay was started by testing how [
125
I]-orexin-A sticks to different filter 
materials. [
125
I]-orexin-A was vacuumed through empty glass fiber (GF/A and GF/B), 
polyvinylidene fluoride (PVDF), mixed cellulose esters or nitrocellulose filters and radioactivity 
from the filters was determined with a Wallac Wizard 1480 γ-counter. The smallest amount of non-
specific binding occurred in glass fiber and PVDF filters and thus different coatings were further 
tested for these filter materials only. 0.5% PEI, 0.1% bovine serum albumin (BSA), 5% milk, and 
0.5% polyvinylpyrrolidone (PVP) + 0.1% Tween 20 were tested for coatings. The coating solution 
was sucked once through the filter and then added on top of the filters to keep them constantly wet. 
Coating was continued for 1 h at room temperature and the filters were washed once with HBM 
before applying 150 μl of 0.1 nM [125I]-orexin-A. After filtering the samples, the filters were 
washed three times with 2 ml of HBM before moving to -counter tubes for measurement. 
Suspended cells: One 10-cm dish of CHO-hOX1 cells was detached and cells were pelleted by 
centrifugation (400 g, 5 min). The cell pellet was suspended in NaBM, containing 0.1% BSA. 50 μl 
of NaBM or SB-334867 (in the final concentration of 10 μM) and 50 μl of 0.02 nM [125I]-orexin-A 
(supplemented with “cold” orexin-A to achieve the final orexin concentration of 0.2 nM) was added 
to multiwell plates or eppendorf tubes, depending on whether filter-bottom plates or individual 
membrane filters were used to separate orexin receptor bound label from the non-bound. The 
reaction was started by addition of 50 μl of cell suspension and the samples were incubated for 90 
min at room temperature.  
Intact cells: 24 h after plating the CHO-hOX1 cells on PEI-coated 48-well plates, the cell 
medium was removed. 100 μl of one of the following buffers was added to the cells: NaBM 
supplemented with different concentrations of CaCl2 (100 nM‒1 mM), TEA-NaBM or high-K
+
-
NaBM (see, 4.6. Inositol phosphate release assay), either with or without 10 µM SB-334867. The 
cell plate was incubated for a few minutes at 37 °C to warm it up. 50 μl of 0.02 or 0.025 nM [125I]-
orexin-A, supplemented with “cold” orexin-A to reach the final orexin concentrations of 1 or 10 
nM, respectively, was added to the cells. The cells were incubated for 10 min at 37 °C. After that, 
the cells were rapidly washed once with cold NaBM. Finally, the cells were detached with 0.2 M 
NaOH and moved to -counter tubes for measurement. 
4.8. Scintillation proximity assay (Paper IV) 
Scintillation proximity assay (SPA) was tested in two different ways: with a conventional way, 
where the scintillation is measured directly from the wells without separation, and with a manner, 
where the incubation medium is carefully removed but the wells are not washed. The latter method 
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seemed to work better in our case as it yielded lower non-specific binding and higher signal-to-
noise ratio. Also incubation time and temperature was easier to control as there was no need for 
overlapping incubation times. 
 CHO-OX1 cells were cultured on a Cytostar-T SPA plate overnight. On the following day, the 
cells were washed with PBS and left in 50 μl of NaBM containing different CaCl2 concentrations 
(100 nM‒1 mM), 20 μM SB-334867 in NaBM or high-K+-NaBM. 50 μl of 0.02 or 0.025 nM 125I-
orexin-A, supplemented with “cold” orexin-A to get the final orexin concentrations of 1 or 10 nM, 
respectively, was added to the cells. The cells were incubated for 10 min at room temperature. For 
the conventional method, the plate was sealed with a clear cover tape and counted with Wallac 
Microbeta Trilux liquid scintillation counter. For the alternative method, the medium was quickly 
and completely removed after the incubation. The plate was then sealed for counting. 
4.9. cAMP release assay (Paper IV) 
CHO-hOX1 cells were cultured on PEI-coated 48-well plates. In some experiments, signaling of the 
Gi-protein was inhibited with pertussis toxin. In these cases, a day after seeding the cells, the 
medium was replaced with medium, which contained 100 ng/ml of pertussis toxin. On the 
following day - or a day after seeding the cells when no pertussis toxin was used - the cells were 
loaded with 5 μCi/ml of [3H]-adenine for two hours. 0.5 mM isobutylmethylxanthine was dissolved 
in NaBM with the aid of bath sonication, and the NaBM was supplemented with different 
concentrations of CaCl2 (10‒1000 μM) and 0.1% BSA. 3 μM of the PKC inhibitor GF-109203X 
was also included into this buffer solution, to prevent the activation of AC by PKC and thus exclude 
the signaling of the Gq-protein (Holmqvist et al., 2005). After loading of the cells with [
3
H]-
adenine, the medium was removed and the cells were washed once with PBS. 100 μl of NaBM, 
including isobutylmethylxanthine and GF-109203X, was added to the cells and the cells were 
incubated for 10 min at 37 °C. 25 μl of 10 μM forskolin, diluted in NaBM, or a mixture of orexin-A 
(0.1‒1000 nM) and forskolin, was added to the wells. The cells were incubated for an additional 10 
min at 37 °C. After that, the supernatant was discarded and 100 μl of cold 0.33 M perchloride acid 
was added instead. The plates were frozen down. 
Dowex columns (Dowex-50W-X8, 200‒400 mesh) were washed with 20 ml of water before 
use. After thawing the samples, the cell debris was centrifuged down (1100 x g, 10min), and the 
samples were loaded to the Dowex columns and 0.33 M perchloride acid was added to give a total 
volume of 1 ml. ATP and ADP fractions were eluted with 2 ml of water into scintillation vials. 5 ml 
of HiSafe 3 scintillation cocktail was added to the vials for counting with Wallac 1414 liquid 
scintillation counter. Alumina columns, prepared from neutral Al2O3, were washed with 8 ml of 0.1 
M imidazole. After the ATP and ADP fractions from the Dowex columns were eluted, Dowex 
columns were placed on top of the washed alumina columns. AMP and cAMP were eluted into the 
alumina columns with 10 ml of water. cAMP was eluated from the alumina columns into big 
scintillation vials with 4 ml of 0.1 M imidazole. 8 ml of HiSafe 3 scintillation cocktail was added to 
the vials before counting. After use, Dowex columns were washed with 2 ml of 1 M hydrochlorid 
acid and 8 ml of water and stored in 0.1 M hydrochloric acid. Alumina columns were washed with 
10 ml of 0.1 M imidazole and stored in 0.1 M imidazole.           
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5. Results and discussion 
5.1. Molecular determinants for orexin agonist distinction (Paper II) 
Orexin receptors could serve as potential drug targets in the treatment of multiple pathological 
states like cancer, addiction or narcolepsy. However, the lack of information of the molecular 
determinants contributing to the ligand binding and functional activity hinders ligand development. 
We used chimaeric orexin receptors to map the orexin receptor areas important for orexin peptide 
distinction. We measured the elevation of intracellular Ca
2+
 after activating chimaeric orexin 
receptors with orexin-A, orexin-B, and [Ala
11
, D-Leu
15
]-orexin-B. As orexin-A should show no 
selectivity between the OX1 and OX2 receptors, it served as an internal control. 
 Exchanging the first quarter of the receptor, from the amino terminus to TM2 (Ch1 and Ch4, 
figure 4), or the last quarter, from TM6 to the carboxyl-terminus (Ch3 and Ch6), caused no 
significant changes in the agonist profile of OX1 or OX2 receptors. In contrast, when the amino 
terminal half, from the amino terminus to TM4 (Ch2 and Ch5), of the receptor was changed, the 
agonist profile dramatically shifted to largely follow the profile of the donor of the N-terminus. 
These results suggested that the second quarter of the orexin receptor, from TM2 to TM4, contains 
the most important determinants of the agonist selectivity. This was confirmed with chimeras, 
where only the second quarter was changed (Ch7 and Ch8). Indeed, exchange of the region between 
these two transmembrane helices only, was enough to change the agonist profile of the receptors. 
TM2 and TM3 have been found to be crucial in determining the orexin receptor subtype selectivity 
for orexin peptides also by other groups. Especially residues Q134 in the TM3 of OX2 receptor and 
V130 in the TM3 of OX1 receptor are needed for the functional activity and binding of orexin 
peptides (Malherbe et al., 2010; Tran et al., 2011). Certain residues in TM5 were also important for 
the binding and functional activity of orexin-A (Tran et al., 2011). 
 The second quarter of the receptor is not the only determinant for agonist distinction as none 
of the chimaeras in this study displayed a fully similar agonist profile to OX1. Interestingly, the 
“subtype-selective” agonists, orexin-B and [Ala11, D-Leu15]-orexin-B, showed differences in their 
receptor activation profiles. That was readily seen with the chimaera, where the second quarter of 
the OX2 was inserted in the OX1 receptor (Ch7). That chimaera was indistinguishable from OX2 
with respect to orexin-B but showed reduced potency for [Ala
11
, D-Leu
15
]-orexin-B. The opposite 
chimaera, where the second quarter of the OX1 was inserted in the OX2 receptor (Ch8), showed 
very low expression and thus the functionality of the chimaera is uncertain. 
For the analysis of the results, it should be considered that the results relate to the potency of 
orexin-A, which is supposed to be non-selective for OX1 and OX2 receptors. This idea is partially 
based on comparison to orexin-B and partially on the apparently similar potency of orexin-A in cell 
lines expressing either receptor subtype. However, the results of Malherbe et al. (2010) suggest that 
similar expression level of OX1 and OX2 produces a similar orexin-A potency; thus its intrinsic 
efficacy may be similar for both receptor subtypes. Nevertheless, it is possible that in some of the 
chimaeras, the actual affinity/potency of orexin-A is affected distorting the comparison. 
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5.2. Molecular determinants of OX1 antagonist SB-334867 binding 
(Paper III) 
The same orexin receptor chimaera approach used in the Paper II was also used to characterise the 
molecular determinants involved in the functional activity of the OX1 receptor-specific antagonist 
SB-334867. As the fluorescence plate reader was no longer accessible, inositol phosphate release 
was now used as a read-out. Similar to the agonists, the second quarter of the orexin receptor seems 
to be the most important area involved in the high affinity interaction with SB-334867. The third 
quarter, from TM4 to the TM6, also contributes in the binding, as was confirmed with the 
chimaeras Ch9 and Ch10. 
 For another OX1 receptor-specific antagonist, SB-674042, and for non-selective orexin 
receptor antagonist, almorexant, the most crucial residues for OX1 receptor binding are located in 
TM3, TM5, TM7, and in the second extracellular loop (Malherbe et al., 2010). Two residues in 
TM3, T135 and V138, were found to be most critical for the selectivity of the OX2 receptor-
selective antagonist EMPA. In another study, TM3 was found to be critical for orexin receptor 
interaction with small molecule antagonists (Tran et al., 2011). TM3 was more closely studied with 
homology modelling and site-directed mutagenesis followed by molecular dynamics stimulations 
(Heifetz et al., 2012). Differences in the amino acid sequences of the TM3 in the OX1 and OX2 
receptors affect the interactions of TM3 with other TMs. These structural differences in TM3 may 
underlie the differences in ligand binding between orexin receptors. Even though the selectivity-
conferring areas of the receptor for antagonists binding are partly conserved, each antagonist seems 
to also interact with specific amino acids, as mutations of certain residues dramatically affect the 
binding and functionality of one antagonist but not the others (Malherbe et al., 2010; Tran et al., 
2011; Heifetz et al., 2012). 
 The agonists (Paper II) and antagonist (Paper III) in our studies did not show similar results in 
all respects. With agonists, none of the chimaeras displayed a fully similar profile to OX1, but with 
SB-334867, several chimeras showed binding of equally high affinity as OX1. Instead, with the 
chimaeras it was difficult to obtain as low binding affinity as SB-334867 for the OX2 receptor. This 
indicates that, in addition to the second quarter of the orexin receptor, there might be other areas 
also involved in the interaction of agonists and antagonists with the receptor.     
5.3. Impact of the expression system on orexin agonist discrimination 
(Paper I) 
Some interesting properties of orexin-B and [Ala
11
, D-Leu
15
]-orexin-B were observed in the study 
described in Paper II. Firstly, [Ala
11
, D-Leu
15
]-orexin-B (as compared to orexin-A) only showed 23-
fold selectivity for OX2 receptor in HEK-293 cells. This is far from the 400-fold selectivity 
originally reported (Asahi et al., 2003). Secondly, in CHO cells, the selectivity was only 14-fold. 
Even lower and also variable selectivity was seen with orexin-B, which showed 9- and 2.6-fold 
selectivity for OX2 in HEK-293 and CHO cells, respectively. The most obvious reason for the 
difference between the cell lines is biased agonism, meaning that orexin receptor could have 
multiple conformations, each of which can differently interact with an agonist (Kenakin, 2012). 
Biased agonism of orexin is also suggested by alanine-scanned orexin peptides, which display 
differences in the activation of Ca
2+
 influx and release (Ammoun et al., 2003). Distinct 
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heteromerisation partners or signal transduction machinery, like diverse G-protein levels, can also 
impact the differences between cell lines (Kukkonen, 2013b).  
5.4. Optimisation of an orexin binding assay (unpublished) 
As part of a co-operative project to find novel orexin-receptor-binding molecules, pharmacological 
analysis of molecules selected by in silico screening is underway. Thus, the development of an 
orexin binding assay, which could be used for this project, was pursued here. One binding assay for 
orexin was already described at the time orexins were found (Sakurai et al., 1998). However, 
instead of intact cells, a new assay for suspended cells, based on filtering, was sought, as this could 
enable faster sample analysis. Both native orexin peptides can be bought labelled with 
125
I, and both 
show high non-specific binding to different surfaces (previous findings). In previous findings, 
orexin-A is suggested to be less "sticky", and thus this was chosen to test. Also, it has better 
availability and applicability to both OX1 and OX2 receptors, in contrast to orexin-B. Binding of 
125
I-orexin-A to plastic ware was reduced with the use of special low binding pipette tips (TipOne 
RPT low retention tips, Starlab) and by adding 0.1% BSA in the NaBM. Different materials (glass 
fiber, polyvinylidene fluoride, mixed cellulose esters and nitrocellulose) and coatings (non-fat milk, 
PEI, BSA, PVP-Tween) were tested in order to reduce binding to filters. Even though some 
materials, especially polyvinylide fluoride filter coated with BSA, appeared promising, the method 
seemed to require so much hands-on work, that attached cells were ultimately used. CHO-hOX1 
cells attached on a multiwell plate also yielded better results than any of the filter materials tested. 
The ultimate protocol only differed from that originally described with respect to incubation time 
(10 min instead of 90 min), the amount of BSA (0.1% instead of 0.5%) and the number of washing 
steps (one step instead of three). Ten minutes does not yield equilibrium binding, but it also causes 
very little internalisation of the receptors (Jäntti et al., 2013).   
5.5. Impact of Ca2+ on orexin binding and PLC activity (Paper IV) 
Elevation of intracellular Ca
2+ 
can be observed after orexin receptor activation (see, 2.3.4.1. 
Elevation of the intracellular calcium concentration) and reduction of extracellular Ca
2+
 
concentration ([Ca
2+
]e) reduces this elevation (Smart et al., 1999; Lund et al., 2000; Ammoun et al., 
2003). This is seen as a shift in the concentration-response curve for orexin. This is not the only 
orexin response to be affected, but instead, for instance, PLA2, PLC, and extracellular signal-
regulated kinase (ERK) responses are affected by reduced [Ca
2+
]e (Lund et al., 2000; Ammoun et 
al., 2006a; Johansson et al., 2007; Turunen et al., 2010). Reduction of extracellular Ca
2+ 
also 
reduces the concentration of intracellular Ca
2+
 (Lund et al., 2000; Ammoun et al., 2003) As, at least, 
PLC and cPLA2 are known to require Ca
2+
 for their activity, their attenuated activation could be 
explained by reduced intracellular Ca
2+
 concentration (Kukkonen, 2013a). In addition to the 
enzymatic activity, extracellular Ca
2+
 may also be needed for orexin to bind to its receptor. Thus 
extracellular Ca
2+
 could regulate orexin signalling at multiple levels, i.e. at the level of orexin 
binding and, at some level of orexin receptor signalling. As this is still largely unclear, the impacts 
of Ca
2+
 on orexin-A binding to OX1 receptor and on orexin-induced PLC activity were studied. 
  PLC activity and 
125
I-orexin-A binding to OX1 was first assessed under different [Ca
2+
]e 
(100 nM ‒ 1 mM). For the binding studies, we used both above described conventional binding 
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assay and SPA. Both orexin-A binding to OX1 and elevation of PLC after OX1 activation were 
significantly decreased after reduction of extracellular Ca
2+
. The concentration-relationship curves 
of Ca
2+
 were highly similar for both binding and PLC activity, indicating that reduced binding could 
fully explain the reduced PLC activity. It has previously been observed, however, that PLC activity 
can also be reduced with pharmacological inhibitors of ROCs and SOCs or by reducing the driving 
force for Ca
2+ 
influx (Johansson et al., 2007). Inhibition of ROCs with TEA-NaBM had a stronger 
impact on PLC activity than inhibition of SOCs with SKF-96365. Even though this has been 
investigated earlier (Johansson et al., 2007), we now used a shorter 10 min activation time to match 
the assays. The impact of membrane depolarisation on orexin-A binding and PLC activity was 
tested with high-K
+
-NaBM. Depolarisation reduced PLC activity much more strongly than binding. 
In addition, inhibition of the ROCs with TEA-NaBM had a more pronounced effect on the PLC 
activity than on binding. Altogether, the results may indicate that extracellular Ca
2+
 plays a dual 
role with respect to the OX1 receptor; Ca
2+
 is necessary for orexin-A binding to OX1 receptor but 
also its influx is needed to act on PLC or other targets, which influences PLC activity.  
PLC isoforms may be directly affected by Ca
2+
 (see, 2.3.4.3. Regulation of lipid signalling). 
Therefore the impact of Ca
2+
 availability/influx is more difficult to analyse for orexin receptors, i.e. 
it is difficult to judge whether Ca
2+
 affect PLC directly or some orexin receptor signalling 
component, in addition to the binding. We therefore turned our focus on the AC regulation. It has 
previously been shown that AC is regulated in multiple ways (by Gs- and Gi-proteins and Gq → 
PLC → PKC pathway) in CHO cells expressing OX1 receptor (see, 2.3.4.2. Regulation of the 
activity of adenylyl cyclase). When the PKC response is eliminated by an inhibitor, pure Gs (low 
potency) and Gi (high potency) responses, which are not directly affected by Ca
2+
, can be seen. We 
thus measured the response via Gi (cells treated with forskolin and the PKC inhibitor, GF109203X). 
The response was even more strongly affected by reduction of [Ca
2+
]e from 1 mM to 100 µM and 
10 µM than the PLC response. That indicates that the impact of extracellular Ca
2+
 is not only 
carried by the binding or some direct effect on the orexin receptor target enzymes. We also assessed 
the Gs response (cells treated with pertussis toxin, forskolin, and GF109203X). Although the 
response cannot be seen at such low orexin-A concentrations as the binding, PLC stimulation, and 
AC inhibition, it also seemed to verify the conclusion by being strongly affected by reduction of 
[Ca
2+
]e.  
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6. Conclusions and future directions 
Some of the factors determining orexin receptor ligand selectivity and binding properties were 
studied in this thesis. First, we roughly mapped the molecular determinants needed for the orexin 
peptide distinction with chimaeric orexin receptors. We found the second quarter of the receptor, 
from the TM2 to TM4, to be the most important part of the orexin receptor needed for the agonist 
selectivity. However, none of the chimaeric receptors displayed fully similar profile to OX1 
indicating that the second quarter is not the only determinant. Similar to the OX1-selective 
antagonist, SB-334867, the second quarter of the orexin receptor is the most crucial in determining 
the selectivity. The third quarter of the receptor was also shown to be able to contribute to the 
functional selectivity. The chimaeric receptor results should assist in the computer modelling of the 
orexin receptors. Valid computer models would improve drug discovery and thus increase the 
chances to find novel orexin receptor binding molecules. 
We also studied the impact of extracellular calcium for orexin binding and signal 
transduction. We showed that reduction of extracellular calcium concentration clearly reduced the 
binding of 
125
I-orexin-A to the OX1 receptor and enzymatic activities of PLC and AC after OX1 
receptor stimulation. The exact target for Ca
2+
 in orexin receptor-peptide interaction should be more 
closely studied as this could offer helpful information also for drug discovery of orexin receptor 
targeting drugs. For instance, as probably at least two different PLC isoforms are involved in orexin 
signalling, the impact of Ca
2+
 should be studied separately for these isoforms. In addition, before 
the effects of extracellular Ca
2+
 on orexin binding and signalling can be fully distinguished, it is 
important to find more selective ways to inhibit the orexin receptor-operated calcium influx. 
 We found that the “OX2-selective” agonist [Ala
11
, D-Leu
15
]-orexin-B showed much lower 
selectivity for the OX2 receptor than originally reported. In addition, the selectivity was dependent 
on the cell type and was lower in CHO than in HEK cells. This was concluded to be caused by 
signal trafficking. Therefore this “orexin subtype-selective” agonist should not be used for receptor 
subtype determination. Signal trafficking should also be considered when new orexin receptor 
agonists are screened.         
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